AMERICAN PSYCHIATRIC ASSOCIATION

2007 ANNUAL MEETING

ADDRESSING PATIENT NEEDSACCESS, PARITY AND HUMANE CARE

160TH ANNUAL MEETINGSAN DIEGO, CALIFORNIA, MAY 19-24, 2007

AMERICAN PSYCHIATRICASSOCIATION

SAN DIEGO, CA + MAY 19 24, 2007

AMERICAN PSYCHIATRIC ASSOCIATIONCONTINUING MEDICAL EDUCATION POLICY ON FULL DISCLOSURE

The American Psychiatric Association requires disclosure, by presenters at CME activities, of any significant financial or other affiliationwith commercial organization(s) regulated by the Food and Drug Administration, which may have a direct or indirect interest in the subjectmatter of the scientific program. A "financial interest" may include, but is not limited to, being a shareholder in the organization ; being onretainer with the organization ; or having research or honoraria paid by the organization . An "affiliation" may include holding a position onan advisory committee or some other role or benefit to a supporting organization .

Under the ACCME Standards for Commercial Support that were in effect when the 2007 Annual Meeting was planned, the existence ofsuch relationships does not necessarily constitute a conflict of interest ; but the prospective audience must be informed of the presenter'saffiliation with every commercial supporter by an acknowledgement in the printed program and verbal or visual disclosure to participants atthe session (disclosure by slide or overhead is required if audiovisual equipment is used for the presentation) . This policy is intended toopenly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgmentsabout the presentation . The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigationaluse of a product not yet approved for this purpose .

The list of presenters below have indicated that either they or an immediate family member has a significant interest or other affiliationwith a commercial supporter of this meeting and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercialservices(s) . The presenter's name and the company's name are listed, along with the page number the presenter appears on in this ProgramBook . The nature of the presenter's relationship with the disclosed company is indicated by the following code : consultant or advisoryboard', full-time employment', research/grant support 3 , speakers' bureau4 , stock or other financial options, other financial or businessrelationships' . If a number has not been assigned, the presenter has not disclosed the relationship to the company .

The second list of presenters, beginning on page ****, have indicated neither they nor an immediate family member has any significantrelationship to disclose . Voting member of the Board of Trustees, Assembly officers, and member of the Scientific Program Committeecannot receive honoraria or travel reimbursement for participating in Industry-Supported Symposia .

Presenter

Manufacturer(s)Gene G. Abel, M.D .

Abel Screening, Inc .Hagop S. Akiskal, M.D .

Abbott Laboratories, Inc . 5 ; AstraZeneca Pharmaceuticals LP 5; Bristol-Myers Squibb Company3' 5 ; Eli Lilly andCompany3. 5 ; GlaxoSmithKline1,3,5; Sanofi-Aventisl,5

Michael H . Allen, M.D .

Abbott Laboratories, Inc . 1 '3 ; Alexza MDC'; AstraZeneca Pharmaceuticals LP ,3 ; Bristol-Myers SquibbCompany' •3; Eli Lilly and Company3 ; Janssen Pharmaceutica Products, LP 3 ; Pfizer Inc . 1,3

Jonathan E. Alpert, M.D.

Abbott Laboratories, Inc 3; Alkermes, Inc 3 ; Aspect Medical Systems3; AstraZeneca Pharmaceuticals LP3;Bristol-Myers Squibb Company3; Cephalon, Inc.3; Cyberonics, Inc3; Eli Lilly and Companyl,3s; ForestLaboratories, Inca; GlaxoSmithKline3;Johnson & Johnson3;Johnson and Johnson Pharmaceutical Researchand Development3 ; Lichtwer Pharma GmbH3 ; Lorex Pharmaceut cals3; National Alliance for Research inSchizophrenia and Depression3; National Institute of Mental Health3 ; Novartis Pharmaceuticals Corporation 3;Organon Pharmaceuticals Inc3' 5 ; PamLab' •3; Pfizer Inc . 3 ; Pharmavite'"3 ; Roche Pharmaceuticals 3 ;Sanofi/Synthelabo3 ; Sanofi-Aventis 3 ; Solvay Pharmaceuticals, Inc.3; Wyeth-Ayerst Laboratories 3

Lori L. Altshuler, M.D .

Abbott Laboratories, Inc . 3 '4; AstraZeneca Pharmaceuticals LP 4'5 ; Bristol-Myers Squibb Companyl ,4 '5; Eli Lillyand Company1,4.5 ; Forest Laboratories, Inc . 1 '4; GlaxoSmithKline4'5; Pfizer Inc. 1 '4 ; Wyeth Pharmaceuticals4

Sonia Ancoli-Israel, Ph.D . Acadia Pharmaceuticals Inc' ; Cephalon, Inc . 1,5 ; King Pharmaceuticals, Inc . 1,5 ; Merck & Co., Inc .' ; NeurocrineBiosciences Inc.1,5 ; Neurogen Corporation' ; NIH Institute3; Pfizer Inc .' ,' ; Sanofi-Aventis 1 '5 ; Sepracor, Inc . 1,5;

Takeda Pharmaceuticals America, Inc . 1,5

Raymond F. Anton, M.D . Alkermes, Inc.' ; AstraZeneca Pharmaceuticals LP' ; Bristol-Myers Squibb Company3 ; Cephalon, Inc . 1,5 ; ForestLaboratories, Inc. 1 ' 3 ; Ortho-McNeil Pharmaceutical, Inc 3 ; Pfizer Inc. 3

William J . Apfeldorf, M.D . Abbott Laboratories, Inc . 5 ; AstraZeneca Pharmaceuticals LP 5 ; Eisai Inca ; Eli Lilly and Company ; ForestLaboratories, Inc. 1,5 ; Janssen Pharmaceutica Products, LP 5; Pfizer Inc . 5; Wyeth Pharmaceuticals 5

Lesley M . Arnold, M.D .

Cypress Bioscience Inc .',3; Eli Lilly and Companyl ,3'5 ; Forest Laboratories, Inc .' ; Pfizer Inc. 1,3,5 ; Sanofi-Aventis 1 A 3; Sepracor, Inc . ; Wyeth Pharmaceuticals 1 . 3

Alan Axelson, M.D .

Eli Lilly and Company5; Novartis Pharmaceuticals Corporations ; Shire Pharmaceuticals Group plc .5Marion A. Becker, Ph.D .

Eli Lilly and Company3Julian Beezhold, M .B.Ch.B. AstraZeneca Pharmaceuticals LPs ; Bristol-Myers Squibb Company5 ; Eli Lilly and Companys ; Janssen-Cilag5

Bernard D . Beitman, M.D . Bristol-Myers Squibb Company'Ruth M. Benca, M.D .

GlaxoSmithKline' ; Neurocrine Biosciences Inc . 1,5; Pfizer Inc . 1,5 ; Sanofi-Aventis'LS; Sepracor, Inc . 1 ' 5 ; TakedaPharmaceuticals America, Inc . 1,5 ; Wyeth Pharmaceuticals 5

Donna S . Bender, Ph.D .

National Institute of Mental Health'Susan R. Bergeson, M.B.A. Abbott Laboratories, Inc .'

John L. Beyer, M.D.

Joseph Biederman, M .D .

Adam Bisaga, M.D .Donald W. Black, M .D.Carlos Blanco Jerez, M .D .Barton J . Blinder, M.D .Paul B. Bohn, M .D .Curley L . Bonds, M.D .Howard E. Book, M .D.Charles L. Bowden, M.D .

Kathleen T. Brady, M.D.

Ronald Brenner, M.D .Thomas E. Brown, Ph .D .

Peter F. Buckley, M.D .

Stephen E. Buie, M.D .Oscar G. Bukstein

Harold L. Burke, Ph .D.

Presenter

Manufacturer(s)Avanir Pharmaceuticals' ; Bristol-Myers Squibb Company3.5; Eisai Inc . 3 ; Elan Pharmaceuticals, Inc .3; Eli Lilly andCompany' •5; GlaxoSmithKline3,5; Janssen Pharmaceutica Products, LP5 ; Myriad Genetics, Inc .3; Pfizer Inc . 3

Abbott Laboratories, Inc . 1 '3 ; Bristol-Myers Squibb Companyl'3 ; Cephalon, Inc . 1,3,5 ; Eli Lilly and Companyl ,3s;Janssen Pharmaceutica Products, LP 1,3; McNeil Consumer Healthcarel ,3s ; National Institute of Child Healthand Human Development3 ; National Institute of Mental Health 3 ; National Institute on Drug Abuse3 ;Novartis Pharmaceuticals Corporation' ,35; NRP3 ; Ortho-McNeil Pharmaceutical, Inc . 1,3 >5 ; Pfizer Inc. 1,3; ShirePharmaceuticals Group plc . 1,3s ; Stanley Medical Research Institute 3 ; UCB PharmalsForest Laboratories, Inc . 5; GlaxoSmithKlinelForest Laboratories, Inc . 1,3,5; Pfizer Inc. 5; Scirex Corporations ; Shire Pharmaceuticals Group plc . 1,2,3,5

Somaxon Pharmaceuticals 3Pfizer Inc . 3Forest Laboratories, Inc 5 ; Pfizer Inc .' ; Wyeth-Ayerst Laboratories 5Abbott Laboratories, Inc.' ; Pfizer Inc .'American Psychological Association Press 4Abbott Laboratories, Inc . 1,3,5 ; AstraZeneca Pharmaceuticals LP' ; Bristol-Myers Squibb Company3 ; ElanPharmaceuticals, Inc . 3 ; Eli Lilly and Companyl ,3s ; GlaxoSmithKline1,3s ;Janssen Pharmaceutica Products,LP 1 .35 ;Johnson and Johnson Pharmaceutical Research and Development3 ; National Institute of MentalHealth 3; Parke-Davis 3; Pfizer Inc . 5; Stanley Medical Research Institute 3; UCB Pharmal

Abbott Laboratories, Inc . 1,3s ; Alkermes, Inc .' ; Cephalon, Inc. 1 ; Eli July and Companyhs; Forest Laboratories,Inc . 1,3,5 ; GlaxoSmithKlinel . 3,5; National Institute on Drug Abuse' ,' ; Ovation Pharmaceuticals, Inc . 1 ; PfizerInc . 1,5; Wyeth Pharmaceuti.cals3AstraZeneca Pharmaceuticals LP' ; Bristol-Myers Squibb Company ; Eli Lilly and Company'

American Psychiatric Press 4 ; Cephalon, Inc .1 ; Eli Lilly and Companyh3 ; McNeil Consumer Healthcarel ,3 ;

Novartis Pharmaceuticals Corporation' ; Shire Pharmaceuticals Group plc . 1,3

Abbott Laboratories, Inc .' ,'; Alamo Pharmaceuticalsl •5; AstraZeneca Pharmaceuticals LP1,3,5 ; Bristol-MyersSquibb Company1,3,5; Eli Lilly and Companyl ,3s ; Janssen Pharmaceutica Products, LP1,3,5 ; Merck & Co., Inc.' ;National Institute of Mental Health3; Pfizer Inc .1,3s; Solvay Pharmaceuticals, Inc .3

Wyeth Pharmaceuticals 5Cephalon, Inc .' ; Eli Lilly and Company3 ; Forest Laboratories, Inc .' ; Novartis Pharmaceuticals Corporations ;Ortho-McNeil Pharmaceutical, Inc .s; Sanofi-Aventis3; Shire Pharmaceuticals Group plc . 1,3sEEG Spectrum International, Inc 2 .6

George Bush, M.D .

Eli Lilly and Company3; Janssen Pharmaceutica Products, LP 5 ; Johnson and Johnson PharmaceuticalResearch and Developments; McNeil Consumer Healthcare3. 5; Novartis Pharmaceuticals Corporations ; PfizerInc . 3 ; Shire Pharmaceuticals Group plc5

Daniel J . Buysse, M.D .

Cephalon, Inc .' ; Eli Lilly and Company' ; GlaxoSmithKline' ; Merck & Co ., Inc . 1 ; Merck, Sharp, and Dohmel ;Neurocrine Biosciences Inc .1 ; Neurogen Corporation' ; Pfizer Inc. 1 . 3 ; Respironics, Inc .' ; Sanofi-Aventisl ,3 ;

Sepracor, Inc .'"3 ; Servier'; Takeda Pharmaceuticals America, Inc 1,3

Nancy Byatt, D.O .

AstraZeneca Pharmaceuticals LP 3 ; Eli Lilly and Company3

Joseph R. Calabrese, M .D . Abbott Laboratories, Inc . 1,3; AstraZeneca Pharmaceuticals LP 1 .3 ; Bristol-Myers Squibb Company' ; Eli Lillyand Companyh 3; G1axoSmithKline 1,3; Janssen Pharmaceutica Products, LP 1 '3 ; Merck & Co., Inc.3; TevaPharmaceutical Industries Ltd.'

William E . Callahan, Jr.,M.D. Bristol-Myers Squibb Company' ; Otsuka America Pharmaceutical, Inc .'

William H . Campbell, M.D. Pfizer Inc .' ; Sanofi-Aventis 5

Joseph Cappelleri

Pfizer Inc 2Stanley N . Caroff, M .D .

Bristol-Myers Squibb Company3 ; Ortho-McNeil Pharmaceutical, Inca ; Pfizer Inc . 3

William T. Carpenter, M.D. AstraZeneca Pharmaceuticals LP' ; Bristol-Myers Squibb Company' ; Cephalon, Inc .' ; T .illyl ; National Instituteof Mental Health'-3; Solvay Pharmaceuticals, Inc . 1 ; Wyeth Pharmaceuticals'

Diana Carter, M.B.B .S .

GlaxoSmithKline5; Wyeth Pharmaceuticals'Daniel E. Casey, M.D .

Abbott Laboratories, Inc ."; Bristol-Myers Squibb Company' ,5; Janssen Pharmaceutica Products, LP 1 '5; PfizerInc."; Solvay Pharmaceuticals, Inc .' ; Sumitomo Pharmaceuticals Co ., Ltd1 ; Wyeth Pharmaceuticals'

David A. Casey, M.D .

Abbott Laboratories, Inc .5; Janssen Pharmaceutica Products, LP 5; Pfizer Inc.5

Alfonso Ceccherini-Nelli, M.D. GlaxoSmithKline2Robert A. Chambers, M .D . Forest Laboratories, Inc .'; National Institute on Drug Abuse 3Kiki D . Chang, M.D .

Abbott Laboratories, Inc . 1 '3 '3 ; AstraZeneca Pharmaceuticals LP1,3,5 ; Eli T .illy and Company" ;GlaxoSmithKline 1 ' 3 ; T .illy'; Otsuka America Pharmaceutical, Inc . 3; Shire Pharmaceuticals Group plc . 1

XXiI

DISCLOSURE INDEX

DISCLOSURE INDEX

PresenterJosepha A. Cheong, M .D .Allen Childs, M .D .Lois W. Choi-Kain, M.D .Henry Chung, M.D .Leslie L. Citrome, M.D .

Daniel J . Clauw, M.D .Anita L. Clayton, M.D .

Emil F. Coccaro, M.D .Judith A. CohenFrancesc Colom, Ph .D .David O. Conant-Norville, M .D.Daniel F. Connor, M .D .Ram Cooppan, M.B.Ch.B .

Manufacturer(s)AstraZeneca Pharmaceuticals LP 5Abbott Laboratories, Inc .'National Institute of Mental Health 3National Institute of Mental Health 3; Pfizer Inc .5Abbott Laboratories, Inc . 5,6 ; AstraZeneca Pharmaceuticals LP 3,5 ; Bristol-Myers Squibb Companyl ,3,6 ; Eli Lillyand Company 1,3,5,6 ; GlaxoSmithKlinet ; Janssen Pharmaceutica Products, LP 3 ; Jazz Pharmaceuticals, Inc .' ;Johnson and Johnson Pharmaceutical Research and Development 6 ; Merck & Co., Inc 6 ; Pfizer Inc . 1sssCypress Bioscience Inc . 1,6Bristol-Myers Squibb Companyl ,3 ; Eli Lilly and Companyt ,3> 5 ; Forest Laboratories, Inc .3; GlaxoSmithKlinel ,3,5 ;

Neuronetics, Inc.3 ; Pfizer Inc . 1 .3,5 ; Sanofi-Aventis3; Vela Pharmaceuticals, Inc.' ; Wyeth Pharmaceuticalsl ,3,5

Abbott Laboratories, Inc . 1,3 ; Eli Lilly and Company3 ; Pfizer Inc .'Department of Health and Human Services 3 ; Guilford Press 4 ; National Institute of Mental Health 3AstraZeneca Pharmaceuticals LP5; Lilly5 ; Sanofi-Aventis 5McNeil Consumer Healthcare 5 ; Novartis Pharmaceuticals CorporationsAstraZeneca Pharmaceuticals LP3; Cephalon, Inc . 5 ; Shire Pharmaceuticals Group plc. 5

Bristol-Myers Squibb Company5; Eli Lilly and Company5 ; Novartis Pharmaceuticals Corporations; NovoNordisk Pharmaceuticals, Inc . 5 ; Pfizer Inc . 5 ; Sanofi-Aventis 5; Takeda Pharmaceuticals America, Inc . 5 ; WyethPharmaceuticals 5Eli Lilly and Company' ; GlaxoSmithKlinel ; Pfizer Inc.'Eli Lilly and Company' ; Janssen Pharmaceutica Products, LP 3AstraZeneca Pharmaceuticals LP3 ; Janssen Pharmaceutica Products, LP 3AstraZeneca Pharmaceuticals LP 1,5 ; Bristol-Myers Squibb Company' ,% Eli Lilly and Company' ; HealthcareTechnology Systems, Inc' ; Intra-Cellular Therapeutics' ; Janssen Pharmaceutica Products, LP 5

Allergan Inc' ; Cypress Bioscience Inc .' ; Merck, Sharp, and Dohmel ; Orphan Medical' ; Pfizer Inc .' ,'; WyethPharmaceuticalsl ,3

Abbott Laboratories, Inc .' ; Eisai Inc . 5Janssen Pharmaceutica Products, LP 3AstraZeneca Pharmaceuticals LP 5; Biovail Corporations ; Wyeth Pharmaceuticals 5Abbott Laboratories, Inc . 1,3,5 ; AstraZeneca Pharmaceuticals LP3; Bristol-Myers Squibb Company3;Cyberonics, Inc . 1,5 ; Eisai Inc . 3 ; Forest Laboratories, Inc . 3 ; Janssen Pharmaceutica Products, LP 3 ; NationalInstitute of Mental Health3Abbott Laboratories, Inc . 3 ; AstraZeneca Pharmaceuticals LP1,3,5 ; Bristol-Myers Squibb Company' • 3 ; Eli Lillyand Companyl ,3; GlaxoSmithKline5; Johnson and Johnson Pharmaceutical Research and Developmentl ,3 ;

Otsuka America Pharmaceutical, Inc 3; Pfizer Inc. 1,5

AstraZeneca Pharmaceuticals LP 1 .3 ; Corcept Therapeutics 3 ; Eli Lilly and Company1 '5; Forest Laboratories,Inc. 1 . 3 ; Medtronics, Inca; National Institute of Mental Health' •3 ; Neuronetics, Inc .' ; NIH Institutel ,3 ; PfizerInc. 6; Wyeth Pharmaceuticalsh 5; Wyeth-Ayerst Laboratories 5

Davangere P . Devanand

Eli Lilly and Company3; Wyeth Pharmaceuticals 3C. Lindsay DeVane, Pharm.D. Bristol-Myers Squibb Company 5 ; Cyberonics, Inca; Eli Lilly and Company' ; GlaxoSmithKlinel ; Janssen

Pharmaceutica Products, LP1,3,5 ; National Institute of Mental Health3; NovaDel Pharma Inc .' ; NovartisPharmaceuticals Corporationl ,3

McNeil Consumer Healthcare3Bristol-Myers Squibb Company'>5; Eli Lilly and Company3; Janssen Pharmaceutica Products, LP 1,5 ; Janssen-Cilagl ,5 ; Pfizer Inc. 1Sepracor,Inc3Bristol-Myers Squibb Company3AstraZeneca Pharmaceuticals LP5; Bristol-Myers Squibb Company5

Eisai Inc .'; Elan Pharmaceuticals, Inca; Eli Lilly and Company' ,5 ; Forest Laboratories, Inc .1,3,5

GlaxoSmithKline3; Myriad Genetics, Inc .' ; Saegis' ; Sanofi-Aventis 3

Cephalon, Inc . 5 ; Pfizer Inc .' ; Sepracor, Inc. 1,5 ; Takeda Pharmaceuticals America, Inc . 5

Eli Lilly and Company3 ; National Foundation for Mental Health3 ; Organon Pharmaceuticals Inca; Sepracor, Inc .

National Institute of Mental Health 3Bristol-Myers Squibb Company5 ; Forest Laboratories, Inc .5 ; GlaxoSmithKline 3,5; Pfizer Inc. 5; WyethPharmaceuticals5

Gabriela Cora-Locatelli, M .D .Barbara A . Cornblatt, Ph.D .Maria R Corral, M.D.Christoph U . Correll, M .D.

Leslie J . Crofford, M.D .

Jeffrey L . Cummings, M .D .Daniella David, M .D .Jonathan S. Davine, M.D .Lori L. Davis, M.D .

Melissa P. DelBello, M.D .

Pedro L. Delgado, M.D .

Mantosh J. Dewan, M.D .Ronald J . Diamond, M.D .

Joel Dimsdale, M .D .Lisa Dixon, M.D .Robert K. Dolgoff, M.D .P. Murali Doriaswamy, M.D .

Christoper L. Drake, Ph.D .Ronald S. Duman, Ph.D .Laura B. Dunn, M .D .James M . Ellison, M.D .

XXIII

Presenter

Manufacturer(s)Raymond A. Faber

Bristol-Myers Squibb Company5; Cephalon, Inc . 5 ; Forest Laboratories, Inc . 5Andrea Fagiolini, M.D .

Bristol-Myers Squibb Company' ; GlaxoSmithKline' ; Merck & Co ., Inc . 3 ; Pfizer Inc . 3Warachal E. Faision, M.D . Bristol-Myers Squibb Company'' ; Forest Laboratories, Inc."; G1axoSmithKline 4; Janssen Pharmaceutica

Products, LP'5; National Institute of Mental Health 3; National Institute on Aging 3 ; Organon PharmaceuticalsInca; Otsuka America Pharmaceutical, Inc ."; Pfizer Inc. 1,3,S

Stephen V. Faraone, Ph .D. Cephalon, Inc .'S; Eli Lilly and Companyl ,3,5; McNeil Consumer Healthcarel ,3,5 ; National Foundation forMental Health3 ; National Institute of Child Health and Human Development3 ; National Institute of MentalHealth 3 ; National Institute of Neurological Disorders and Stroke3; National Institute on Drug Abuse 3 ; NovenPharmaceuticals, Inc .' ; Shire Pharmaceuticals Group plc. 1,3s

Maurizio Fava, M.D .

Abbott Laboratories, Inc 3 ; Alkermes, Inc .3; Aspect Medical Systems'- 3; AstraZeneca Pharmaceuticals LP1 .3.5; BayerCorporation' ; Biovail Corporation' ; Boehringer-Ingelheim Pharmaceuticals 5 ; BrainCells, Inc.' ; Bristol-MyersSquibb Company',5; Cephalon, Inc . 1,3,5 ; Compellis Pharmaceuticalsh 6 ; Cypress Bioscience Inc.' ; CypressPharmaceuticals' ; Dov Pharmaceuticals' ; Eli Lilly and Company' ,3,5; EPIX'; Fabre Kramer Pharmaceuticals Inc .' ;Forest Laboratories, Inc .' ,3,5 ; GlaxoSmithKline 1 ."5 ; Grunenthal GmBH1 ; Janssen Pharmaceutica Products, LP' ; JazzPharmaceuticals, Inc .' ; Johnson and Johnson Pharmaceutical Research and Development' ,3 ; Knoll PharmaceuticalCompany'; Lichtwer Pharma GmbH3; Lorex Pharmaceuticals3; Lundbeckl; MedAvante, Inc .' ; Neuronetics, Inc .' ;Novartis Pharmaceuticals Corporation' ,3,5 ; Nutrition 21, Inc' ; Organon Pharmaceuticals Inc'-3,5; PamLab'3 ; PfizerInc.' ,3,5 ; Pharmacia & Upjohn" ; PharmaStar'5; Pharmavite'3; Roche Pharmaceuticals' ,3 ; Sanofi/Synthelabo' ,3 ;Sanofi-Aventis13; Sepracor, Inc.'3; Solvay Pharmaceuticals, Inc .13 ; Somaxon Pharmaceuticals'; SomersetPharmaceuticals Inc .'; Wyeth Pharmaceuticals' ,3,5 ; Wyeth-Ayerst Laboratories' ,3,5

Jan Fawcett, M .D .

Abbott Laboratories, Inc .'; Eli Lilly and Company5; National Institute of Mental Health 3; Wyeth Pharmaceuticals'Francisco Fernandez, M.D . Bristol-Myers Squibb Company3 ; Cyberonics, Inc .3 ; Esai-Pfizer3 ; NIH Institute3; Pfizer Inc . 3; Sumitomo

Pharmaceuticals Co ., Ltd3 ; Wyeth Pharmaceutical'sRobert L. Findling, M.D .

Abbott Laboratories, Inc.'; AstraZeneca Pharmaceuticals LP' ; Bristol-Myers Squibb Company' ; Eli Lilly andCompany'; Forest Laboratories, Inc .' ; GlaxoSmithKline' ; Johnson and Johnson Pharmaceutical Research andDevelopment' ; Novartis Pharmaceuticals Corporation' ; Otsuka America Pharmaceutical, Inc .' ; Pfizer Inc .' ;Sanofi-Aventis' ; Shire Pharmaceuticals Group plc .'s ; Solvay Pharmaceuticals, Inc .' ; Wyeth Pharmaceuticals'

Naomi A. Fineberg

AstraZeneca Pharmaceuticals LP5; Bristol-Myers Squibb Company3 ; Cephalon, Inc .3 ; GlaxoSmithKline'David P . Folsom, M.D .

National Institute of Mental Health 4Timothy W . Fong, M.D .

Forest Laboratories, Inc . 5; Ortho-McNeil Pharmaceutical, Inca; Reckitt-Benkiser5Brent P. Forester, M .D .

Abbott Laboratories, Inc. 3. 5 ; AstraZeneca Pharmaceuticals LP 5; Eli Lilly and Company5; GlaxoSmithKline3;Janssen Pharmaceutica Products, LP 5 ; Novartis Pharmaceuticals Corporations; Pfizer Inc3,5

Philippe Fossati, M .D .

Eli Lilly and Company'; Servier 3Ellen Frank, Ph.D . Eli Lilly and Company' ; Forest Laboratories, Inc . 3 ; Forest Research Institute3 ; Guilford Press 4; Guliford

Pharmaceuticals' ; H. Lundbeck A/S, Guilford Press 4; Lundbeck'; National Institute of Mental Health 3 ;Novartis Pharmaceuticals Corporation'; Pfizer Inc.' ; Servier'

Gordon Frankle, M .D .

AstraZeneca Pharmaceuticals LP 3 ; Bristol-Myers Squibb Company3 ; Fujisawa Pharmaceutical, Co.3Nancy Frasure-Smith, Ph .D. GlaxoSmith.Kline 3 ; IsodisNatura3 ; Solvay Pharmaceuticals, Inc. 5Marlene P. Freeman, M.D. Arizona Disease Control Research Commission 3 ; AstraZeneca Pharmaceuticals LPs ; Eli Lilly and Company5 ;

Forest Laboratories, Inc . 3 ; National Institute of Mental Health3 ; Pfizer Inc .' ; Pronova Biocare3; Reliant'; TheInstitute for Mental Health Research of Arizona 3; THER-X'; U .S. Food and Drug Administration 3

Fred Frese, M.D. Abbott Laboratories, Inc .'; AstraZeneca Pharmaceuticals LP' ; Bristol-Myers Squibb Company' ; Eli Lilly andCompany' ; Janssen Pharmaceutica Products, LP' ; Novartis Pharmaceuticals Corporation' ; Otsuka AmericaPharmaceutical, Inc .' ; Pfizer Inc .'

Robert D . Friedberg, Ph.D. Guilford Publications 4Joseph I . Friedman, M .D . Eli Lilly and Company3Mark A. Frye, M.D .

Abbott Laboratories, Inc .t ,3,5 ; American Foundation for Suicide Prevention 3; AstraZeneca PharmaceuticalsLP15 ; Bristol-Myers Squibb Company's ; Cephalon, Inc . 5 ; Eli Lilly and Company', ' ; G1axoSmithKline 1,3 ;Indevus Pharmaceuticals, Inc .5 ; Janssen Pharmaceutica Products, LP 5 ; Janssen-Cilag'; Johnson and JohnsonPharmaceutical Research and Development' ; National Institute of Mental Health3; Novartis PharmaceuticalsCorporation15 ; Ortho-McNeil Pharmaceutical, Inc .' ; Otsuka America Pharmaceutical, Inc .'3,5 ; Pfizer Inc .' 3,5 ;Solvay Pharmaceuticals, Inc 3 ; Stanley Medical Research Institute 3 ; Wyeth Pharmaceuticals'

Kenneth D. Gadow, Ph .D . Checkmate Plush

Wolfgang Gaebel, M .D .

AstraZeneca Pharmaceuticals LP'5 ; Bristol-Myers Squibb Company' 3,5 ; Eli Lilly and Company' ;GlaxoSmithKline5 ; H. Lundbeck A/S' ; Janssen-Cilag' ,3s ; Lilly'3,5 ; Lundbeck'3,5 ; Novartis PharmaceuticalsCorporation' ; Sanofi-Aventis5; Wyeth Pharmaceuticals' 3

XXTV

DISCLOSURE INDEX

DISCLOSURE INDEX

PresenterFred H. Gage, Ph.D .James E . Galvin, M .D .

Kerning Gao, M .D .

Mark S. George, M.D .

Tony P. George, M.D .

Nassir Ghaemi, M.D .Mona H. Gill, M .D .Michael J . Gitlin

Alexander H. Glassman, M.D .Tasha Glenn, Ph.D .Ira D. Glick, M .D .

Donald C. Goff, M.D .

Harold W. Goforth, M .D .Joseph F. Goldberg, M.D .

Gabe Goldfeder, M.A .

Morris B. Goldman, M.D .Irwin Goldstein

Frederick K. Goodwin, M.D .

Jon E. Grant, M.D .Jack A. Grebb, M.D .George T . Grossberg, M.D .

Linda S . Grossman, Ph.D .Heinz Grunze, M.D .

Sanjay Gupta, M.D .

Raquel E . Gur, M .D .Robert E. HalesMartin Harrow, Ph.D .Philip D. Harvey, Ph.D .

Manufacturer(s)BrainCells, Inc . 1 '6 ; Celgene Corporation ; Ceregene, Inc. 1 . 6 ; Stem Cells Inc . 1,6Eisai Inc . 5 ; Eli T ily and Company3 ; Forest Laboratories, Inc . 5; National Institute of Mental Health 3; NationalInstitute on Aging3 ; Novartis Pharmaceuticals Corporations ; Ortho-McNeil Pharmaceutical, Inc . 5 ; Pfizer Inc . 5AstraZeneca Pharmaceuticals LP5

Aventis Pharmaceuticals, Inc .' ; Biovail Corporation3; Cortex Pharmaceuticals, Inca ; Cyberonics, Inc . 1,3,5 ;GlaxoSmithKline 3;Jazz Pharmaceuticals, Inc . 1 ; National Institute of Health 3 ; Neuronetics, Inc . 1,3; NeuroPace,Inc . 1,3

Eli Lilly and Company5; National Alliance for Research in Schizophrenia and Depression 3 ; National Instituteon Drug Abuse3; Pfizer Inc . 1 "5 ; Targacept, Inc 3Abbott Laboratories, Inca ; GlaxoSmithKline3 ; Janssen Pharmaceutica Products, LP 3 ; Pfizer IncaWyeth Pharmaceuticals 5AstraZeneca Pharmaceuticals LP 5; Bristol-Myers Squibb Company 5 ; Cephalon, Inc . 5 ; Eli T .illy and Company5;GlaxoSmithKline 5 ; Pfizer Inc . 5Pfizer Inc.5Chronorecord Association4AstraZeneca Pharmaceuticals LP 5; Bristol-Myers Squibb Company 5 ; Eli Lilly and Company 5 ; ForestLaboratories, Inc.6; GlaxoSmithKline 3 ; Janssen Pharmaceutica Products, LP5; Johnson and JohnsonPharmaceutical Research and Development6; Pfizer Inc .5 ; Shire Pharmaceuticals Group plc . 3,5; SolvayPharmaceuticals, Inc . 1,3

AstraZeneca Pharmaceuticals LP 1; Bristol-Myers Squibb Company 1,3,5 ; Cephalon, Inca; Eli T .illy andCompany5 ; GlaxoSmithKlineh3; Janssen Pharmaceutica Products, LP1,3,5 ; Merck & Co., Inc .' ; Pfizer Inc . 1,3,5

Wyeth Pharmaceuticals'Bristol-Myers Squibb Companyh5 ; Forest Laboratories, Inc . 3; Pfizer Inca; Sepracor, IncaAbbott Laboratories, Inc . 1,3,5 ; AstraZeneca Pharmaceuticals LP3. 5; Bristol-Myers Squibb Company3,5 ; Eli Lillyand Company1,3,5 ; GlaxoSmithKlinel ,3,5 ; Janssen Pharmaceutica Products, LP 3 ; Pfizer Inc 3.5AstraZeneca Pharmaceuticals LP3; Bristol-Myers Squibb Company3 ; Forest Laboratories, Inca; JanssenPharmaceutica Products, LP3 ; Myriad Genetics, Inca ; Otsuka America Pharmaceutical, Inca; Pfizer Inca ;Sanofi-Aventis 3National Institute of Mental Health3; Otsuka America Pharmaceutical, Inc . 3 ; Pfizer IncaBayer Corporation' ; Eli Lilly and Company' ; Johnson and Johnson Pharmaceutical Research andDevelopment' ; Pfizer Inc .' ; Proctor & Gamble Pharmaceuticals, Inc.'Abbott Laboratories, Inca ; Bristol-Myers Squibb Company 1,3,5 ; Eli T .illy and Company 1,3,5; ForestLaboratories, Inca; GlaxoSmithKline 1,3,5 ; Janssen Pharmaceutica Products, LP 3 ; Pfizer Inc . 1,3,5 ; Sanofi-Aventis3; Solvay Pharmaceuticals, Inc . 3Forest Laboratories, Inca ; GlaxoSmithKline 3; Somaxon Pharmaceuticalsl ,3

Bristol-Myers Squibb Companyz ,6

Abbott Laboratories, Inc. 1' 3 ; AstraZeneca Pharmaceuticals LP 1 ; Bristol-Myers Squibb Companyl,3 ; Eli T .illyand Company3 ; Forest Laboratories, Inc . 1,3 ; GlaxoSmithKline'" 3 ; Janssen Pharmaceutica Products, LP1,3 ;Janssen-Cilag' ; T .illyl •3; Myriad Genetics, Inca ; National Institute on Aging3; Novartis PharmaceuticalsCorporationl' 3 ; Ono Pharmaceuticals, Inca; Pfizer Inc .1 .3 ; Sanofi-Aventis' ; Sepracor, Inc.' ; WyethPharmaceuticalsl ,3

National Institute of Mental Health3AstraZeneca Pharmaceuticals LP' ,5 ; Eli Lilly and Company5; GlaxoSmithKline1 ' 5 ; Janssen-Cilags; NovartisPharmaceuticals Corporation' ; Pfizer Inc .',5 ; UCB Pharma 3Abbott Laboratories, Inc.3' 6 ; AstraZeneca Pharmaceuticals LP 3.5 ; Bristol-Myers Squibb Company5 ; Eli Lillyand Companyl ,3s ; Forest Laboratories, Inc .' ,3,5; GlaxoSmithKline 3,5; Johnson and Johnson PharmaceuticalResearch and Development3; Memory Pharmaceuticals3; Myriad Genetics, Inca ; Neurochem, Inca; OnoPharmaceuticals, Inca ; Otsuka America Pharmaceutical, Inca; Pfizer Inc3'5; Solvay Pharmaceuticals, Inca;Somaxon Pharmaceuticals 3NIH Institute3Bristol-Myers Squibb Company3,5

National Institute of Mental Health 3Solvay Pharmaceuticals, Inc., Pfizer Inc.'

Presenter

Manufacturer(s)

David Healy, M.D .

AstraZeneca Pharmaceuticals LP 5 ; Teva Pharmaceutical Industries Ltd . 1,4

David J. Hellerstein, M .D . Bristol-Myers Squibb Company3; Eli Lilly and Company3; Forest Laboratories, Inc .3; GlaxoSmithKline3

David C. Henderson,,M.D . Bristol-Myers Squibb Companyl ,3 ; Eli Lilly and Company3 ; Pfizer Inc . 1 '3 ; Solvay Pharmaceuticals, Inc .'

Charles H . Hennekens, M.D. Amgen, Inc' ; AstraZeneca Pharmaceuticals LP 1 .5 ; Bayer Corporation' ; Biovail Corporation' ; Bristol-MyersSquibb Companyl ,5 ; G1axoSmithKline' ; McNeil Consumer Healthcare'; Merck & Co., Inc .' ; NovartisPharmaceuticals Corporation' ; Pfizer Inc.1 '5 ; Solvay Pharmaceuticals, Inc .' ; TAP Pharmaceuticals, Inc' ; WyethPharmaceuticals'

Jacqueline Henschke, M.D. AstraZeneca Pharmaceuticals LP 3Paula L. Hensley, M.D .

Amgen, Inc4; Pfizer Inc .

Barry K. Herman, M.D .

Pfizer Inc .6

Napoleon B. Higgins, M .D. AstraZeneca Pharmaceuticals LP 5; GlaxoSmithKline 5 ; Janssen Pharmaceutica Products, LP 5 ; McNeilConsumer Healthcare 5; Novartis Pharmaceuticals Corporations ; Shire Pharmaceuticals Group plc . 5

Marynell Hinton, M.A.

Professional Risk Management Services, Inc .2Max Hirshkowitz, Ph .D.

Aventis Pharmaceuticals, Inc .3 ; Cephalon, Inc.5; GlaxoSmithKline 3 ; Lundbeck3; Merck, Sharp, and Dohme 3 ;National Institute of Health3; Neurocrine Biosciences Inc. 3; Respironics, Inc . 3 ; Sanofi-Aventisl ,3,5 ; TakedaPharmaceuticals America, Inc . 3s

Eric Hollander, M.D .

Abbott Laboratories, Inc.3 ; Lilly3; National Institute of Mental Health 3 ; National Institute of NeurologicalDisorders and Stroke3 ; National Institute on Drug Abuse 3 ; Neuropharm'"6 ; Ortho-McNeil Pharmaceutical,Inc .' ; Solvay Pharmaceuticals, Inc 3 ; Somaxon Pharmaceuticals 3 ; U.S. Food and Drug Administration3; UCBPharma3

Ray C. Hsiao, M.D .

Bristol-Myers Squibb Company ; Pfizer Inc .6

Rona Hu, M.D .

AstraZeneca Pharmaceuticals LP 1 ' 3 ; Bristol-Myers Squibb Companyl ,3; Eli T illy and Company' ; ForestLaboratories, Inc . 3; Janssen Pharmaceutica Products, LP' ,3 ; Pfizer Inc .'

Michael Y. Hwang, M.D .

Janssen Pharmaceutica Products, LP 1,5

Dan V. Iosifescu, M .D .

Aspect Medical Systems 1,3; Cephalon, Inc . 1 .3 ; Eli Lilly and Company'; Forest Laboratories, Inc . 3 ; JanssenPharmaceutica Products, LP3 ; Pfizer Inc . 5

Naveed Iqbal, M .D. AstraZeneca Pharmaceuticals LP 1,3; Bristol-Myers Squibb CompanyL3 5 ; Forest Laboratories, Inca; ForestPharmaceuticals, Inc 3 ; Janssen Pharmaceutica Products, LP1,3s ; Myriad Genetics, Inca; Otsuka AmericaPharmaceutical, Inc. 1,3s; Pfizer Inc.3; Sanofi-Aventis3

Philip G . Janicak, M .D .

Abbott Laboratories, Inc 5 ; AstraZeneca Pharmaceuticals LP',3,5; Bristol-Myers Squibb Companyl ,3s ;JanssenPharmaceutica Products, LP1,3s ; Neuronetics, Inca ; Pfizer Inc .' ; Solvay Pharmaceuticals, Inca

Geetha Jayaram, M.D .

,5; Bristol-Myers Squibb Company' ; Cephalon, Inc . 5 ; GlaxoSmithKline5; Janssen Pharmaceutica Products,LPs; Wyeth Pharmaceutical's

James W. Jefferson, M .D . Abbott Laboratories, Inc . 5 ; AstraZeneca Pharmaceuticals LP 5 ; Bristol-Myers Squibb Company5,6 ; Eli Lilly andCompany 5 ; Forest Laboratories, Inc . 5; GlaxoSmithKline' ,'" 6 ; Healthcare Technology Systems, Inc2' 4; NovartisPharmaceuticals Corporations ; Pfizer Inc . 5; Schwartz Pharma5; Shire Pharmaceuticals Group plc.5 ; SolvayPharmaceuticals, Inc 5; Wyeth Pharmaceuticals 5

Dilip V. Jeste, M .D .

AstraZeneca Pharmaceuticals LP 1 '4 ; Bristol-Myers Squibb Company1 ' 4 ; Eli Lilly and Companyh 4;JanssenPharmaceutica Products, LP1,3.4 ; National Institute of Mental Health 3 ; Otsuka America Pharmaceutical, Inc.' ;Solvay Pharmaceuticals, Inc .' ; Wyeth Pharmaceuticals'

Hadine Joffe, M .D .

Berlex Inc. 4; Eli T .illy and Company5; GlaxoSmithKline 5 ; Pfizer Inc . 5 ; Sanofi-Aventis 4; Sepracor, Inc . 3; WyethPharmaceuticals 4

Bankole Johnson, M.D .

Alkermes, Inc .' ; Forest Laboratories, Inc .' ; GlaxoSmithKlinel ; Intranasal Therapeutics, Inc .' ; Johnson andJohnson Pharmaceutical Research and Development' ; Ortho-McNeil Pharmaceutical, Inc .' ; Sanofi-Aventis' ;TransOral Pharmaceuticals, Inc'

Bradley R. Johnson, M.D . Forest Laboratories, Inc .'

Joel P. Johnson, M.D .

GlaxoSmithKline4

Rene Kahn

AstraZeneca Pharmaceuticals LP's ; Bristol-Myers Squibb Companyl ,3,5 ; Eli T .illy and Company's ;

GlaxoSmithKline' ; Johnson and Johnson Pharmaceutical Research and Development'; Merck, Sharp, andDohmel ,5 ; Organon Pharmaceuticals Inc'" 5; Pfizer Inc.','; Sanofi-Aventis"5

Thomas A. Kaleita, Ph.D .

Cephalon, Inc . 1,3

Ronald L. Kamm, M .D .

Pfizer Inc . 6

Kyle M. Kampman, M.D . Alkermes, Inca ; Cephalon, Inc . 5 ; Forest Laboratories, Inc . 5

XXVI

DISCLOSURE INDEX

DISCLOSURE INDEX

Presenter

Manufacturer(s)John M. Kane, M.D .

Abbott Laboratories, Inc. 1,5; AstraZeneca Pharmaceuticals LP 1; Bristol-Myers Squibb Companyl' 5; Eli Lillyand Company' ; Janssen Pharmaceutica Products, LP 1,5 ; Janssen-Cilagl ,5; Johnson and JohnsonPharmaceutical Research and Development' ; Lundbeck; MDS Pharma Services' ; MedAvante6; Pfizer Inc. 1,5 ;Roche Pharmaceuticals' ; Solvay Pharmaceuticals, Inc . ; Wyeth-Ayerst Laboratories'

Shimi Kang, M.D .

Alkermes, Inc . 1,5 ; AstraZeneca Pharmaceuticals LP5; Cephalon, Inc . ; Eli Lilly and Company5 ; JanssenPharmaceutica Products, LP 5

Shitij Kapur

Forest Laboratories, Inc . 5 ; Schwartz Pharma5Wayne J . Katon, M.D .

Eli Lilly and Company 4 ; Forest Laboratories, Inc . 4; G1axoSmithKline 5 ;John A Hartford Foundation 3;National Institute of Mental Health 3 ; Wyeth-Ayerst Laboratories4

David J. Katzelnick, M .D . Abbott Laboratories, Inc. 1,3,5; AstraZeneca Pharmaceuticals LP 3 ; Forest Laboratories, Inc .5 ;G1axoSmithKline3' 5 ; Johnson and Johnson Pharmaceutical Research and Development' ; Lilly-5; Merck & Co.,Inc . 1 ' 3; Novartis Pharmaceuticals Corporation3,5; Organon Pharmaceuticals Inc' ; Pfizer Inc. 1 . 3 ; Pharmacia &Upjohn'; Robert Wood Johnson Foundation' ; Solvay Pharmaceuticals, Inc . 3 ; Wyeth Pharmaceuticals)

Paul E. Keck, M.D .

Abbott Laboratories, Inc. 1 . 3 ; AstraZeneca Pharmaceuticals LP 1 .3 ; Bristol-Myers Squibb Companyl ,3; Eli Lillyand Companyh3; GlaxoSmithKlinel,3; Janssen Pharmaceutica Products, LP 1,3 ; Memory Pharmaceuticals' ;Merck & Co., Inc 3 ; National Institute of Mental Health 3 ; National Institute on Drug Abuse3 ; NeurocrineBiosciences Inc .' ; Organon Pharmaceuticals Inca ; Ortho-McNeil Pharmaceutical, Inc . 1 .3; Pfizer Inc .' ,' ; ShirePharmaceuticals Group plc . 1 ; Stanley Medical Research Institute 3; UCB Pharma 3

George A. Keepers, M.D . Eli Tilly and Company5Samuel J. Keith, M.D.

AstraZeneca Pharmaceuticals LP3; Bristol-Myers Squibb Companyl'3 ; Cyberonics, Inca; Eli T .illy andCompany3; Forest Laboratories, Inca; GlaxoSmithKline3; Janssen-Cilag 1,3,5 ; Merck, Sharp, and Dohme 3 ;Novartis Pharmaceuticals Corporationl ,3 ; Pfizer Inc . 1,3,5 ; Pharmacia & Upjohn3; Wyeth Pharmaceuticals 3

John R. Kelsoe, M .D .

GlaxoSmithKline5; Psynomics, Inc 4Ronald C . Kessler, Ph.D .

Bristol-Myers Squibb Company3; Eli T .illy and Companyl' 3 ; GlaxoSmithKlinel ; Ortho-McNeilPharmaceutical, Inca ; Pfizer Inc . 1,3 ; Wyeth-Ayerst Laboratories )

Terence A . Ketter, M.D .

Abbott Laboratories, Inc . 1,3,5 ; AstraZeneca Pharmaceuticals LP',3,5 ; Bristol-Myers Squibb Companyl ,3s;Cephalon, Inc .' ; Corcept Therapeutics' ; Eisai Inca ; Elan Pharmaceuticals, Inc . 1 .3 ; Eli Lilly and Companyl>3 5 ;Forest Laboratories, Inc . 1 ; GlaxoSmithKline 1 '3,5 ; Janssen Pharmaceutica Products, LP1,3s; JazzPharmaceuticals, Inc. ; Merck & Co ., Inc.' ; Novartis Pharmaceuticals Corporation1,3 .5; Pfizer Inc . 5; ShirePharmaceuticals Group plc . 1,3,5; Solvay Pharmaceuticals, Inc . 1,3; UCB Pharma'; Wyeth Pharmaceuticalsl ,3

Sabrina J . Khan, M .D .

Eli Lilly and Company6; Merck & Co., Inc.6; Pfizer Inc .6 ; Schering-Plough CorporationClinton D . Kilts, Ph .D .

Forest Laboratories, Inc . 1 '3; H. Lundbeck A/S 1 ; Janssen Pharmaceutica Products, LP 3; National Institute ofMental Health3 ; National Institute on Drug Abuse3; Solvay Pharmaceuticals, Inc .'

David G. Kingdon, M.D .

AstraZeneca Pharmaceuticals LP5; Bristol-Myers Squibb Company' ; Eli Tilly and Company '5; GuilfordPress4; Janssen-Cilag5 ; Pfizer Inca

Herbert D . Kleber, M .D .

Alkermes, Inc .' ; Reckitt-Benkiserl ,3

Harold W. Koenigsberg, MD. Janssen Pharmaceutica Products, LP 3George F. Koob, Ph.D.

Addex Pharmaceuticals' ; Alkermes, Inc . 1 ; Forest Pharmaceuticals, Inc .' ; Hythiam Inc .'Lorrin M. Koran, M.D .

Cypress Bioscience Inc . 1,6; Eli Lilly and Company3; Forest Laboratories, Inc 3 .5; Jazz Pharmaceuticals, Inc.3;Ortho-McNeil Pharmaceutical, Inca; Somaxon Pharmaceuticals3

Thomas R. Kosten, M.D . Alkermes, Inc .'; Bristol-Myers Squibb Company' ; Cephalon, Inc.'; Gerson Lehman Group'; Johnson andJohnson Pharmaceutical Research and Developmentl' 6 ; Merck, Sharp, and Dohmel ; National Institute ofMental Health3 ; National Institute on Drug Abusel ,3 ; Novartis Pharmaceuticals Corporation' ; Pfizer Inc . 6

Christopher J . Kratochvil, M.D. Abbott Laboratories, Inc . 1,3 ; AstraZeneca Pharmaceuticals LP 1; Boehringer-Ingelheim Pharmaceuticals' ;Cephalon, Inc . 1 .3 ; Eli Lilly and Company1,3,5; McNeil Consumer Healthcare3; National Institute of MentalHealthl ,3 ; Organon Pharmaceuticals Inc' ; Pfizer Inc .' ; Shire Pharmaceuticals Group plc .1 ,3

K Ranga Krishnan, M.D .

Abbott Laboratories, Inc .' ; Amgen, Inc' ; Bristol-Myers Squibb Company' ; CeNeRx1 ; Cyberonics, Inc .' ; EliLilly and Company' ; GlaxoSmithKlinel ; H. Lundbeck A/S' ; Johnson and Johnson Pharmaceutical Researchand Development'; Merck & Co ., Inc .' ; Novartis Pharmaceuticals Corporation 3 ; NPS Pharmaceuticals' ;Organon Pharmaceuticals Inc' ; Otsuka America Pharmaceutical, Inc .' ; Pfizer Inc .' ; Sepracor, Inc.' ; SomersetPharmaceuticals Inc . 1 ; Vela Pharmaceuticals, Inc .' ; Wyeth Pharmaceuticals'

Meir H. Kryger, M.D.

Cephalon, Inc . 1 ; National Institute of Health3 ; Takeda Pharmaceuticals America, Inc .'Andrew D. Krystal, M.D . King Pharmaceuticals, Inc .' ; Merck & Co ., Inca; Neurocrine Biosciences Inc . 1 .3 ; Neurogen Corporation' ;

Pfizer Inc.1 ' 3 ; Respironics, Inc . 1 '3 ; Sanofi-Aventisl ,3; Sepracor, Inc . 1 '3; Somaxon Pharmaceuticalsl ,3; TakedaPharmaceuticals America, Inc .'

XXVII

DISCLOSURE INDEX

Presenter

Manufacturer(s)

John H. Krystal, M .D .

AstraZeneca Pharmaceuticals LP 1 ; Bristol-Myers Squibb Company' ; Eli Lilly and Company' ; ForestLaboratories, Inc. ; GlaxoSmithKline1 ; Janssen Research Foundation' ; Merz Pharmaceuticals' ; OrganonPharmaceuticals Inc? ; Pfizer Inc . 1 ; Takeda Industries'

Jayashri Kulkarni, M.B.B .S . AstraZeneca Pharmaceuticals LP 3; Bristol-Myers Squibb Company3; Eli Lilly and Company3; JanssenPharmaceutica Products, LP 3; Janssen-Cilag3; National Alliance for Research in Schizophrenia andDepression' ; Novartis Pharmaceuticals Corporation'; Organon Pharmaceuticals Inca ; Sanofi/Synthelabo 3 ;Sanofi-Aventis3; Servier3 ; Stanley Medical Research Institute 3

Elisabeth J . S . Kunkel, M.D. Forest Laboratories, Inc . 5Helen H. Kyomen, M.D .

AstraZeneca Pharmaceuticals LP, Bayer Corporation ; AstraZeneca Pharmaceuticals LP 1 ; BayerCorporationh3; Bristol-Myers Squibb Company'' 3 ; Eli Lilly and Company'L3 ; GlaxoSmithKlinel ; John AHartford Foundation3; Merck & Co., Inc.' ; Merck & Co ; National Institute on Aging3 ; NIH Institute3;Novartis Pharmaceuticals Corporation'; Pfizer Inc 1 ,3 ; Roche Pharmaceudcals 1,3 ; The John A. HartfordFoundation3; UCB Pharmal'3 ; Veterans Administration 3; Wyeth-Ayerst Laboratoriesl ,3

Samuel J . Langer

Bristol-Myers Squibb Company -2Alan Langlieb, M.D .

Eli Lilly and Company3,5

John Lauriello, M.D .

Abel Screening, Inc.3; AstraZeneca Pharmaceuticals LP',3,5 ; Bristol-Myers Squibb Companyl ,3s ; Eli T .illy andCompanyl'3; Janssen Pharmaceutica Products, LP1,3,5 ; Janssen-Cilagl ,3s ; Pfizer Inc .' ,5

William B . Lawson, M.D .

Abbott Laboratories, Inc . 3; Bristol-Myers Squibb Company5;Janssen Pharmaceutica Products, LP1 ; PfizerInc .'

Arthur L. Lazarus, M.D .

AstraZeneca Pharmaceuticals LP 2,6Hochang B . Lee, M .D .

GlaxoSmithKline 3,5

Steven J . Lee, M .D .

Cephalon, Inc .'; Forest Laboratories, Inc . 5

Andrew C. Leon, Ph.D .

Cortex Pharmaceuticals, Inc' ; Cyberonics, Inc.'; MedAvante6; Pfizer Inc 4; Vanda Pharmaceuticals4

Francois Lesperance, M.D. GlaxoSmithKline3'5 ; IsodisNatura3 ; Lundbeck5; Servier' ; Wyeth Pharmaceuticals5Stefan Leucht, M .D .

Bristol-Myers Squibb Company's ; Eli Lilly and Company' ,3,5 ; H. Lundbeck A/S 5 ; Janssen PharmaceuticaProducts, LP1 .5 ; Janssen-Cilag5;Johnson and Johnson Pharmaceutical Research and Development's ;

Lundbeck5; Pfizer Inc.5; Sanofi-Aventisl ,3,s

James L. Levenson, M .D.

Eli T .illy and Company'Frances R. Levin, M.D .

Alkermes, Inc .' ; AstraZeneca Pharmaceuticals LP 1.3 ; Cephalon, Inc .' ; Eli Lilly and Company3 ; Ortho-McNeilPharmaceutical, Inc .' ,3; Shire Pharmaceuticals Group plc . 1 '3; UCB Pharma3

Petros Levounis, M.D .

Alkermes, Inc . 5; AstraZeneca Pharmaceuticals LP 5 ; Cephalon, Inc. 5; Forest Laboratories, Inc .5 ; Reckitt-Benkiser5; Takeda Pharmaceuticals America, Inc . 5

Roberto Lewis-Fernandez, M.D. Eli Lilly and Companyl' 3; GlaxoSmithKline 3 ; National Institute of Mental Health 3 ; Pfizer Inc .3Jeffrey A. Lieberman, M .D. Acadia Pharmaceuticals Inca; AstraZeneca Pharmaceuticals LP 1 '3; Bristol-Myers Squibb Companyl ,3; Eli Lilly

and Company'; GlaxoSmithKline1,3 ; Janssen Pharmaceutica Products, LP 1,3 ; Johnson and JohnsonPharmaceutical Research and Development' ; Merck, Sharp, and Dohme 3; Novartis PharmaceuticalsCorporation!; Organon Pharmaceuticals Inc' ,3 ; Pfizer Inc.'"3 ; Repligen4; Sanofi-Avendsl

Russell F. Lim, M.D .

Abbott Laboratories, Inc.5; AstraZeneca Pharmaceuticals LP 5

Jean-Pierre Lindenmayer, M .D. Alamo Pharmaceuticals3; AstraZeneca Pharmaceuticals LP 3 ; Eli T illy and Companyl •3 ; Janssen PharmaceuticaProducts, LP' ,3 ; Janssen-Cilag3; National Institute of Mental Health 3; Pfizer Inc. 3

Maria D . Llorente, M .D .

Abbott Laboratories, Inc.'; Bristol-Myers Squibb Company5 ; Veterans Administration

Sheila M . Loboprabhu, M .D. AstraZeneca Pharmaceuticals LP 5Leslie P . Lundt, M.D . Cephalon, Inc. 1,3s ; Eli Lilly and Company 3 ; Forest Laboratories, Inc . 3' 5 ; GlaxoSmithKline 3; Merck & Co .,

Inc .3 ; Merck, Sharp, and Dohme3; Pfizer Inc .5,6 ; Sanofi-Aventis 3 '5 ; Sepracor, Inc . 1,3,5 ; Shire PharmaceuticalsGroup plc . 3 ; Takeda Pharmaceuticals America, Inc . 1,3,5 ; Targacept, Inc3,5 ; Wyeth Pharmaceuticals5

Shari I. Lusskin, M .D .

AstraZeneca Pharmaceuticals LP5; Wyeth Pharmaceuticals 5

Robert B . Lydiard, M.D .

Abbott Laboratories, Inc.'; AstraZeneca Pharmaceuticals LP' ; Bristol-Myers Squibb Company3 ; Cephalon,Inc . 3 ; Eli T .illy and Company1,3,5 ; Forest Laboratories, Inc . 1 . 3 ; McNeil Consumer Healthcare3; NovartisPharmaceuticals Corporation' ; Roche Pharmaceuticals' ; Sanofi-AventislL 3 ; Wyeth Pharmaceuticals3

Constantine G. Lyketsos, M.D. AstraZeneca Pharmaceuticals LP 1,4; Eisai Inc . 4; Forest Laboratories, Inc . 3' 4; G1axoSmithKlineLL 3 ; H. LundbeckA/S4; National Institute of Health3; Novartis Pharmaceuticals Corporation 4; Pfizer Inc . 4

Kathryn J. Macdonald, M .D. AstraZeneca Pharmaceuticals LP'sSean Mackey, M.D .

Eli Lilly and Company5 ; Pfizer Inc . 5

Vishal Madaan, MD

GlaxoSmithKline4

XXVIII

DISCLOSURE INDEX

Presenter

Alan S. Maisel, M.D .

Catherine L . Mancini, M.D .

Christina Mangurian, M.D .Lauren B. Marangell, M.D .

Stephen R. Marder, M.D .

John C. Markowitz, M .D .Robert W. Marvin, M.D .Prakash S. Masand, M.D .

Thomas L. Matthews, M .D .Helen S. Mayberg, M.D .Linda C. Mayes, M.D.Thomas H. McGlashan, M.D .Keith McBurnett, Ph.D .Susan L. McElroy, M.D .

Joseph P . McEvoy, M.D.

Patrick D. McGorry, M.D.Roger S. McIntyre, M.D .

Jacqueline M. Melonas, J .D .Samantha E. Meltzer-Brody, M.D .Matthew A. Menza, M.D .

Jonathan M. Meyer, M.D .Eric MickRoumen V. Milev, Ph.D .

Alexander L. Miller, M.D .

William R . Miller, Ph.D .Jacobo E . Mintzer, M .D .

Manufacturer(s)Abbott Laboratories, Inc . 3 ; Bayer Corporation 3; Johnson and Johnson Pharmaceutical Research andDevelopmentsAstraZeneca Pharmaceuticals LP 3 ; Cephalon, Inc.3 ; Eli Lilly and Company3; GlaxoSmithKline 1 .3,5 ; JanssenPharmaceutica Products, LP 3 ; National Institute of Mental Health3 ; Novartis Pharmaceuticals Corporation3;Pfizer Inc .3Bristol-Myers Squibb Company4; Janssen Pharmaceutica Products, LP 3Aspect Medical Systems' ; Bristol-Myers Squibb Company3; Cyberonics, Inc .13; Eli Lilly and Company1,3 ;Forest Laboratories, Inc .' ; GlaxoSmithKlinel ; Medtronics, Inc .' ; National Institute of Health3; Neuronetics,Inc 3 ; Novartis Pharmaceuticals Corporation' ; Pfizer Inc .' ; Stanley Medical Research Institute 3Bristol-Myers Squibb Company' ; G1axoSmithKline 1 ; Merck, Sharp, and Dohme' ; Otsuka AmericaPharmaceutical, Inc.' ; Pfizer Inc.' ; Solvay Pharmaceuticals, Inc .'National Alliance for Research in Schizophrenia and Depression ; National Institute of Mental Health3National Institute of Mental Health 3Abbott Laboratories, Inc .3'5; Alkermes, Inc .' ; AstraZeneca Pharmaceuticals LP1,3,5 ; Bristol-Myers Squibb Company 1,3,5,6;Cephalon, Inc. 1,3; Eli Lilly and Company3 ; Forest Laboratories, Inc .1,5 ; GlaxoSmithKline' ,3, s ; GiilifordPharmaceuticals' ; Janssen Pharmaceutica Products, LP' 3s;Jazz Pharmaceuticals, Inc .' ; Organon Pharmaceuticals Inc' ;Ortho-McNeil Pharmaceutical, Inc .3; Pfizer Inc ."; Targacept, Inc . 1; Wyeth Pharmaceuticalsl ,35

AstraZeneca Pharmaceuticals LPs ; Shire Pharmaceuticals Group plc . 5Advanced Neuromodulation Systems, Inc . 1 .4 ; Cyberonics, Inc .'National Institute of Health 3Eli Lilly and Company3Cephalon, Inca ; McNeil Consumer Healthcare3 ; NRP3 ; Shire Pharmaceuticals Group picaAbbott Laboratories, Inc.' ; AstraZeneca Pharmaceuticals LP 3.4 ; Bristol-Myers Squibb Company3. 4; Eisai Inca ;Eli Lilly and Company'3; Forest Laboratories, Inc . 3,4; GlaxoSmithKlinel ; Janssen Pharmaceutica Products,LP'; Johnson and Johnson Pharmaceutical Research and Development 4 ; National Institute of Mental Health 3 ;Novartis Pharmaceuticals Corporation' ; Ortho-McNeil Pharmaceutical, Inc .13; Pfizer Inc3.4 ; Sanofi-Aventis 3' 4 ; Somaxon Pharmaceuticals3,4; Stanley Medical Research Institute4 ; Wyeth Pharmaceuticals'AstraZeneca Pharmaceuticals LP3; Bristol-Myers Squibb Company3' 5 ; Eli T .illy and Company3, ';GlaxoSmithKline1,3 ; Janssen-Cilag3. 5 ; Organon Pharmaceuticals Inca ; Otsuka America Pharmaceutical, Inc 5 ;Pharmaceutical Product Development, IncaAstraZeneca Pharmaceuticals LP, Janssen-Cilag3; Janssen-Cilag3AstraZeneca Pharmaceuticals LP'3,5; Biovail Corporation',';Bristol-Myers Squibb Company'; Eli Lilly andCompany'' ; GlaxoSmithKlinel ,3s ; H. Lundbeck A/S 5 ; Janssen Pharmaceutica Products, LP 1,5; Merck & Co .,Inc .3 ; Merck, Sharp, and Dohme 3 ; Organon Pharmaceuticals Inc'' ; Oryx Pharmaceuticals, Inc ."; PfizerInc.'' ; Prestwick Pharmaceuticals, Inc .'5; Servier 3 ; Wyeth Pharmaceuticals'3,5

Professional Risk Management Services, Inc .2GlaxoSmithKline3AstraZeneca Pharmaceuticals LP3; Bristol-Myers Squibb Companyl ,3,5 ; Eli Lilly and Companyl ,3,5 ; ForestLaboratories, Inc .13; National Institute of Mental Health' ; National Institute of Neurological Disorders andStrokel 3; Sanofi-Aventis13,5 ; Sepracor, Inc .'3,5; Takeda Pharmaceuticals America, Inc .13,5 ; WyethPharmaceuticals 3Bristol-Myers Squibb Company1,3,4,5 ; Janssen Pharmaceutica Products, LPL4,5 ; Pfizer Inc .13,4,5

McNeil Consumer Healthcarel 3 ; National Institute of Mental Health3; Shire Pharmaceuticals Group plc .'AstraZeneca Pharmaceuticals LP'3s ; Biovail Corporation' ; Eli Lilly and Companyl ,3,5 ; H. Lundbeck A/S3 ;Wyeth Pharmaceuticals' ; Wyeth-Ayerst Laboratories'AstraZeneca Pharmaceuticals LPL3,5 ; Bristol-Myers Squibb CompanyL 3s ; Eli Lilly and Company3 ; ForestLaboratories, Inca ; InforMedix, Inc .' ; Janssen Pharmaceutica Products, LPL3' 5 ; Organon PharmaceuticalsInca; Pfizer Inc. 1,3,5

National Institute of Health 3 ; National Institute on Drug Abuse 3Abbott Laboratories, Inc . 1,3,5 ; AstraZeneca Pharmaceuticals LP1,3,5 ; Bristol-Myers Squibb Company1,3,5 ;Capital Research Companies"; Eisai Inc .13,5; Eli Lilly and Companyl ,3,5 ; Forest Laboratories, Inc . 1,3,5 ; JanssenPharmaceutica Products, LP 3 ; Johnson and Johnson Pharmaceutical Research and DevelopmentL 3,5 ;Mitsubishi Pharmaceutical Corporation3; National Institute of Health 3 ; National Institute of Mental Health 3;National Institute on Aging3 ; Neurochem, Inca; NIH Institute 3 ; Novartis Pharmaceuticals Corporation3;Otsuka America Pharmaceutical, Inc .1 5 ; Pfizer Inc .L3,5 ; Predix Pharmaceuticals''; Sanofi-Aventis'3,5; VoyagerPharmaceutical Corp3

XXIX

Presenter

Asha S. Mishra, M .D .Shaila Misri, F .R.C.P .C .

Ramin Mojtabai, M.D .Jacques Montplaisir, M .D .Quinton E. Moss, M.D .David A. Mrazek, M .D .Rodrigo A. Munoz, M.D .

Philip R . Muskin, M.D .

Hugh Myrick, M .D .

David K. Nace, M.D .Ziad H. Nahas, M.D .Joseph C. Napoli, M.D .

Meera Narasimhan, M.D .

Kenneth C. Nash, M.D .Henry A. Nasrallah, M .D .

Randy J. NelsonCharles B . Nemeroff, M .D .

David N. Neubauer, M.D .John W. Newcomer, M.D .

D. Jeffrey Newport, M.D .

Anthony T. Ng, M.D .

Andrew A. Nierenberg, M.D .

Andrei Novac, M .D .Keith H. Nuechterlein, Ph.D .

Edward V. Nunes, M.D .H. George Nurnberg, M.D .

Manufacturer(s)AstraZeneca Pharmaceuticals LP 5 ; Bristol-Myers Squibb Company 5AstraZeneca Pharmaceuticals LP 1,3; Biovail Corporations; G1axoSmithKline 1,5; H. Lundbeck A/S'"3. 5 ; JanssenPharmaceutica Products, LP 5 ; Wyeth PharmaceuticalstssAstraZeneca Pharmaceuticals LP 3; Bristol-Myers Squibb Companyl ,3

Boehringer-Ingelheim Pharmaceuticals' ; GlaxoSmithKline 3; Jazz Pharmaceuticals, Inc . 3; Servier'

National Institute of Mental Health 3; Pfizer Inc . 5

AssureRxtEli Lilly and Company3AstraZeneca Pharmaceuticals LPs ; Bristol-Myers Squibb Company' ,5 ; Cephalon, Inc. 1 ' 5 ; Eli Lilly andCompany5; Forest Laboratories, Inc . 5 ; GlaxoSmithKline5; Janssen Pharmaceutica Products, LP5 ; NationalInstitute of Mental Health' ; Otsuka America Pharmaceutical, Inc . 5 ; Pfizer Inc . 1,5

Abbott Laboratories, Inc .5 ; AstraZeneca Pharmaceuticals LP 5 ; Bristol-Myers Squibb Company3,5 ; ForestLaboratories, Inc. 3,5 ; National Institute of Alcohol Abuse and Alcoholism 3 ; National Institute on DrugAbuse3; Ortho-McNeil Pharmaceutical, Inc .3 ; Pfizer Inc .3McKesson Corporation, 2; McKesson CorporationCyberonics, Inc . 1 .3 ; Neuronetics, Inc. 1,3

AstraZeneca Pharmaceuticals LP5; GlaxoSmithKline5; Pfizer Inc. 5

Abbott Laboratories, Inc .' ; AstraZeneca Pharmaceuticals LP 3.5 ; Bristol-Myers Squibb Companyl ,3,5 ; Eli T lilyand Companyl ,5 ; Forest Laboratories, Inc 3; Janssen Pharmaceutica Products, LP 3,5 ; National Institute ofHealth3 ; National Institute on Drug Abuse3>5 ; Pfizer Inc . 5Eli Lilly and Company5 ; Novartis Pharmaceuticals CorporationsAbbott Laboratories, Inc . 1,5 ; AstraZeneca Pharmaceuticals LP1,3,5 ; Eli Lilly and Company3 ; JanssenPharmaceutica Products, LP1,3,5 ; Pfizer Inc . 1,3s; Shire Pharmaceuticals Group plc.' , '

Merck & Co., Inc.' ; National Institute of Mental Health 3

Abbott Laboratories, Inc. 1 .5 ; Acadia Pharmaceuticals Inch 6; AstraZeneca Pharmaceuticals LP 3; Bristol-MyersSquibb Companyh3; CeNeRx4; Cyberonics, Inc .' ; Cypress Bioscience Inc .1,6 ; Eli Lilly and Company' ; ForestLaboratories, Inc . 1,3; GlaxoSmithKline1,5 ; Janssen Pharmaceutica Products, LP',3,5; National Alliance forResearch in Schizophrenia and Depression3; National Institute of Mental Health 3 ; NovaDel Pharma Inc .t ;Otsuka America Pharmaceutical, Inc .' ; Pfizer Inc .' ,3s ; Reevax4 ; UCB Pharma'; Wyeth Pharmaceuticalsl,3

Neurocrine Biosciences Inc .' ; Pfizer Inc .' ; Sanofi-Aventls' ,5; Takeda Pharmaceuticals America, Inc . 1,5

AstraZeneca Pharmaceuticals LP 1 ; Bristol-Myers Squibb Company'' 3 ; Compact Clinicals4 ; GlaxoSmithKline' ;Janssen Pharmaceutica Products, LP 1,3 ; National Alliance for Research in Schizophrenia and Depression 3 ;National Institute of Mental Health 3; Organon Pharmaceuticals Inc' ; Pfizer Inc. 1 "3 ; Sidney R BaerFoundation3; Solvay Pharmaceuticals, Inc .' ; Wyeth Pharmaceuticals'AstraZeneca Pharmaceuticals LP 5 ; Eli Lilly and Company3,5 ; GlaxoSmithKline3,5 ; Janssen PharmaceuticaProducts, LP 3 ; Pfizer Inc . 5 ; Wyeth Pharmaceuticals 3Eli Lilly and Company5; Pfizer Inc .'; Substance Abuse and Mental Health Services Administration/ Centerfor Substance Abuse Treatment'sAstraZeneca Pharmaceuticals LP 3; Bristol-Myers Squibb Companyl,3,5 ; Cederroth International3; Cyberonics,Inc . 3,5 ; Eli Lilly and Companyl,3,5; Forest Laboratories, Inc . 3 '5; Genaissance Pharmaceuticals' ;GlaxoSmithKline 1,3, s ; Innapharma, Inc .' ; Janssen-Cilag'; Lichtwer Pharma GmbH 3 ; MilleniumPharmaceuticals, Inc . 3; National Alliance for Research in Schizophrenia and Depression 3; National Instituteof Mental Health'"3 ; Neuronetics, Inc .' ; Novartis Pharmaceuticals Corporation' ; Organon PharmaceuticalsInc 1,3s ; Pfizer Inc . 1,3 ; Sepracor, Inc .' ; Shire Pharmaceuticals Group plc. 1 ; Somerset Pharmaceuticals Inc .' ;Stanley Medical Research Institute 3 ; Sumitomo Pharmaceuticals Co ., Ltd' ; Wyeth Pharmaceuticalsl ,3s

Forest Laboratories, Inc . 5; GlaxoSmithKline 5 ; Pfizer Inc . 5Janssen Pharmaceutica Products, LP 3 ; National Institute of Mental Health, Janssen Pharmaceutica Products,LP 3Alkermes, Inc . 1,5 ; Cephalon, Inc.5Abbott Laboratories, Inc. 3" 5 ; Bristol-Myers Squibb Companyl ,3,5 ; Eli T,illy and Company l,3,5 ;

GlaxoSmithKline'" 5 ; Lipha Pharma3; Parke-Davis3 ; Pfizer Inc. 1,3s ; Wyeth Pharmaceuticals 3,5

DISCLOSURE INDEX

DISCLOSURE INDEX

PresenterDavid J. Nutt, D.M.

Mary B. O'Malley, M.D .Stephanie O'Malley, Ph .D .Cheryl A . Oncken, M.D.Lewis A. Opler, M.D .Urban p. Osby, M .D .

David W. Oslin, M .D .Michael J. Ostacher, M.D .

Sagar V. Parikh, M .D .

Lawrence T. Park, M.D .Joseph J . ParksAmita R. Patel, M.D .

Martin P. Paulus, M.D .Roy H. Perlis, Ph .D .

Eric D. Peselow, M.D.Francois C . Petitjean, M.D .Barbara A . Phillips, M.D .Katharine A. Phillips, M .D .Edmond H. Pi, M.D .Harold A. Pincus, M .D .

Mark H. Pollack, M .D .

Bruce G. Pollock, M.D .

Marc N. Potenza, M.D .

Annelle B. Primm, M.D .Jefferson B. Prince, M.D .Andres J . Pumariega, M.D .Paul M.Ramirez, Ph.D .

Manufacturer(s)Asahi' ; Cephalon, Inc . 5; Cypress Bioscience Inc . 1 '5 ; Eli Lilly and Companyl ,5 ; Esteve1; GlaxoSmithKlinel ,3,5,6;Janssen Pharmaceutica Products, LP1,3'5 ; Lundbeck 3' 5 ; MDS Pharma Services 1,3,5 ; Novartis PharmaceuticalsCorporationl ,3 '5; Organon Pharmaceuticals Inc1,3s; Passion for Life' ; Pfizer Inc . 1,3s ; Pharmacia & Upjohnl ,5;Reckitt-Benkiser 5 ; Servier3; Takeda Pharmaceuticals America, Inc . 1,5; Therascil ; Wyeth Pharmaceuticals3 s ;Yamanouchi3Cephalon, Inc .3.5 ; G1axoSmithKline 3; Merck & Co ., Inc 3 ; Neurocrine Biosciences Inc .'; Pfizer Inc. 5 ; Sepracor, Inc. 5Alkermes, Inc . 3National Institute on Drug Abuse 3 ; Pfizer Inc . 1,3

Multi-Health Systems, Inc .4AstraZeneca Pharmaceuticals LP 1 .5 ; Bristol-Myers Squibb Company' ,'; Eli Lilly and Companyl ,5 ; NationalAlliance for Research in Schizophrenia and Depression 3 ; Pfizer Inc . 1sNIH Institute, Robert Wood Johnson Foundation 3AstraZeneca Pharmaceuticals LP5; Bristol-Myers Squibb Company5 ; G1axoSmithKline 5; JanssenPharmaceutica Products, LP 5; Pfizer Inc. 5AstraZeneca Pharmaceuticals LP 1 .3 ; Biovail Corporationh 3 ; Eli Lilly and Company3 ; G1axoSmithKline3 ;Janssen Pharmaceutica Products, LP3 ; Novartis Pharmaceuticals Corporation3; Wyeth Pharmaceuticalsl ,3

Abbott Laboratories, Inc . 3; Bristol-Myers Squibb Company3; Janssen Pharmaceutica Products, LP 3Abbott Laboratories, Inc . 3; Comprehensive Neurosciences Incorporated' ; Medical Letters and Sciences 5AstraZeneca Pharmaceuticals LP 5; Bristol-Myers Squibb Company5 ; Cyberonics, Inc . 5 ; Eli Lilly andCompany5 ; Forest Laboratories, Inc . 5; G1axoSmithKline 5; Novartis Pharmaceuticals Corporations ; Sanofi-Aventis 5; Takeda Pharmaceuticals America, Inc . 5; Wyeth Pharmaceuticals 5GlaxoSmithKlinelAstraZeneca Pharmaceuticals LP 1 ; Bristol-Myers Squibb Company' ; Eli Lilly and Company ;GIaxoSmithKline' ; Pfizer Inc .'Forest Laboratories, Inc . 5 ; GlaxoSmithKline5; Pfizer Inc.5Bristol-Myers Squibb Company' ,5 ; Janssen-Cilagh5; Sanofi-Aventis'Boehringer-Ingelheim Pharmaceuticals' ; GlaxoSmithKline'American Psychiatric Press 4 ; Forest Laboratories, Inc . 3; National Institute of Mental Health 3; UCB Pharma3Pfizer Inc. 5

Academy of Managed Care Pharmacy (AMCP) Horizons, LLC 4 ; American Psychiatric Press 4; AtlanticPhilanthropies 3; Bimark Medical Education4; Cardinal Health, Inc . 4 ; Cisco Systems' ; Columbia University2;Community Care Behavioral Health Organization/UPMC Health Plan' ; Comprehensive NeuroScience, Inc .,Medical Information Technologies¢; Current Opinion in Psychiatry/Lippincott, William and Wilkins 4 ;National Institute of Child Health and Human Development3 ; National Institute of Mental Health 3; NationalInstitute on Drug Abuse 3 ; New York-Presbyterian Hospital2 ; RAND Corporation; Raymond John WeanFoundation 3 ; Substance Abuse and Mental Health Services Administration/ Center for Substance AbuseTreatment3; The Heinz Endowments 3 ; The John A. Hartford Foundation3 ; The Robert Wood JohnsonFoundation 3 ; Veterans Administration 3AstraZeneca Pharmaceuticals LP 1 ; Bristol-Myers Squibb Companyl' 3 ; Cephalon, Inc. 1,3; Eli Lilly andCompanyl ,3 s ; Forest Laboratories, Inc . 1,3 s ; G1axoSmithKline1,3s; Janssen Pharmaceutica Products, LP1,3s ;National Alliance for Research in Schizophrenia and Depression 3; National Institute of Mental Health 3 ;National Institute on Drug Abuse 3 ; Novartis Pharmaceuticals Corporation' ; Pfizer Inc .' ,3 '5 ; Sanofi-Aventls1 ;Sepracor, Inc. 1,3 ; UCB Pharmal ,3 ; Wyeth Pharmaceuticalsl ,3sForest Laboratories, Inc . 1 ' 5 ; Janssen Pharmaceutica Products, LP 3; Lundbeck'•5 ; National Institute of MentalHealth3Gerson Lehman Group' ; GlaxoSmithKlinel ; National Institute of Alcohol Abuse and Alcoholism' ; NationalInstitute of Child Health and Human Development' ; National Institute of Neurological Disorders andStroke' ; National Institute on Drug Abusel ,3 ; NIH Institute' • 3; Somaxon Pharmaceuticals )AstraZeneca Pharmaceuticals LP 1 ; Eli Lilly and Company' ; Pfizer Inc.'McNeil Consumer Healthcare, Shire Pharmaceuticals Group plc . 1Eli Lilly and Company'; Forest Laboratories, Inc . 5Multi-Health Systems, Inc .4

PresenterMark H. Rapaport, M.D .

Natalia L. Rasgon, M.Ed .

Lawrence P. Reagan, Ph .D .William E . Reichman, M .D .

John A. Renner, M.D .Perry F. Renshaw, M .D .Roy O. Resnikoff, M.D.

Victor I . Reus, M.D .Charles F. Reynolds, M .D .Michelle B . Riba, M.D .Steven Richeimer, M.D .Elliott Richelson, M .D .

Paula D . Riggs, M .D .

Trevor Robbins, Ph .D .

Delbert G. Robinson, M .D .Robert G. Robinson, M.D .Steven P . Roose, M.D .

Jerrold F. Rosenbaum

Cherise Rosen, Ph .D .Robert Rosenheck, M.D .

Richard N . Rosenthal, M.D .A. John Rush, M.D .

Deirdre M. Ryan, F.R.C.P.C.Abe M. Rychik, J .D .Perminder Sachdev, M.D .Gary S . Sachs, M .D .

Ihsan M . Salloum, M .D .

XXXII

DISCLOSURE INDEX

Manufacturer(s)Abbott Laboratories, Inc. 3 ; AstraZeneca Pharmaceuticals LP 3 ; BrainCells, Inc .' ; Cyberonics, Inc . 1,3,5 ; Eli Lillyand Companyl ,3,5 ; Forest Laboratories, Inc . 1,3s,6 ; GlaxoSmithKline1,3 .5; Janssen Pharmaceutica Products,LPi,3,5 ; National Alliance for Research in Schizophrenia and Depression 3; National Institute of MentalHealthl ,3; National Institute on Drug Abuse'; Neurocrine Biosciences Inc .' ; Novartis PharmaceuticalsCorporation' ,3,5; Pfizer Inc. 1,3,5 ; Pharmacia & Upjohn 3; Roche Pharmaceuticals' ; Sanofi-Aventish3 ; SolvayPharmaceuticals, Inc . 1 '3; Stanley Medical Research Institute 3 ; Sumitomo Pharmaceuticals Co ., Ltd' ; UCBPharma3; Wyeth Pharmaceuticals 1,3 s

Abbott Laboratories, Inc. 1,3,5 ; Eli Lilly and Company5; Forest Laboratories, Inc . 1,3,5 ; GlaxoSmithKline1,5 ;

Novartis Pharmaceuticals Corporations ; Pfizer Inc .' ; Wyeth Pharmaceuticals ),5

Servierl ,3

Eisai Inc . 3 ; Forest Laboratories, Inc . 1,3,5 ; Fujisawa Pharmaceutical, Co.3; Myriad Genetics, Inc .3 ; Ortho-McNeil Pharmaceutical, Inc . 1 .5; Pfizer Inc.5; Sanofi-Aventis3; Takeda Pharmaceuticals America, Inc . 3Alkermes, Inc . 5; Cephalon, Inc . 5 ;Johnson & Johnson ; Reckitt-Benkiser 5 ; Shire Pharmaceuticals Group p1c . 1Eli Lilly and Company3; GlaxoSmithKlinel ; Kyowa Hakkol ; Novartis Pharmaceuticals Corporation'AstraZeneca Pharmaceuticals LP4; Bristol-Myers Squibb Company4 ; Eli Lilly and Company4; ForestLaboratories, Inc. 4 ; GlaxoSmithKline 4 ; Pfizer Inc4; Wyeth Pharmaceuticals¢Nabi Pharmaceuticals 3Forest Laboratories, Inc . 3Eli Lilly and Company' ; GlaxoSmithKline 1 ; Pfizer Inc .'Merck & Co., Inc .%; Pfizer Inc .5; Purdue Pharma L .P . 5Eli Lilly and Company' ; Janssen Pharmaceutica Products, LP3; Neuronetics, Inc . 3 ; Pfizer Inc . 5 ; Sanofi-Aventis' ; Somaxon Pharmaceuticals'Eli Lilly and Company3; McNeil Consumer Healthcare 3 ; National Institute on Drug Abuse 3 ; ShirePharmaceuticals Group plc. 1,5

CeNeS Pharmaceuticals; Cephalon, Inc . 1 =5; Cortex Pharmaceuticals, Inc 1 '5 ; Eli Lilly and Companyl ,3 ;

GlaxoSmithKline' ,3; Pfizer Inc.3 ; Roche Pharmaceuticalsl ,5

Bristol-Myers Squibb Company3; Janssen Pharmaceutica Products, LP 3

Avanir Pharmaceuticals )Bristol-Myers Squibb Company3; Eli Lilly and Companyl'3 ; Forest Laboratories, Inc . 1 .3 ; NovartisPharmaceuticals Corporation' ; Organon Pharmaceuticals Inc' ; Wyeth Pharmaceuticals 1,3

Bristol-Myers Squibb Company' ; Eli Lilly and Company' ; Forest Laboratories, Inc .' ; NovartisPharmaceuticals Corporation' ; Organon Pharmaceuticals Inc' ; Pfizer Inc . ; Roche Pharmaceuticals' ; Sanofi-Aventis' ; Sepracor, Inc . 1National Institute of Mental Health 3AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Janssen Pharmaceutica Products, LP ;Wyeth PharmaceuticalsAlkermes, Inc .' ; Cephalon, Inc .' ; Forest Laboratories, Inc .'Advanced Neuromodulation Systems, Inc .' ; Best Practice Project Management, Inc .' ; Bristol-Myers SquibbCompany'; Cyberonics, Inc . 1 "5 ; Eli Lilly and Company' ; Forest Laboratories, Inc . 1 ' 5 ; Gerson Lehman Group' ;GlaxoSmithKline 1,5 ; Guilford Publications¢; Healthcare Technology Systems, Inca ; Jazz Pharmaceuticals,Inc .'; Merck & Co ., Inc . 1,5 ; National Institute of Mental Health 3 ; Neuronetics, Inc .' ; NIH Institute 3 ; NovartisPharmaceuticals Corporation' ; Ono Pharmaceuticals, Inc .' ; Organon Pharmaceuticals Inc'; PersonalityDisorder Research Corporation' ; Pfizer Inc . ; Robert Wood Johnson Foundation 3 ; Stanley Medical ResearchInstitute3 ; Urban Institute' ; Wyeth Pharmaceuticals' ; Wyeth-Ayerst Laboratories'Wyeth Pharmaceuticals3Professional Risk Management Services, Inc . 4AstraZeneca Pharmaceuticals LPs ; Pfizer Inc. 5Abbott Laboratories, Inc . 1,3,5; AstraZeneca Pharmaceuticals LP 1 '5; Bristol-Myers Squibb Companyl ,3s ; EliLilly and Company's; GlaxoSmithKlinel ,3s ;Janssen Pharmaceutica Products, LP1,3,5 ; MemoryPharmaceuticals' ; Merck & Co ., Inc . 1 ; Merck, Sharp, and Dohmel ; National Institute of Mental Health 3 ;Novartis Pharmaceuticals Corporationl' 3; Otsuka America Pharmaceutical, Inc . 1 "5 ; Pfizer Inc . 1,3,5; Sanofi-Aventis 5 ; Shire Pharmaceuticals Group plc . 1 ; Stanley Medical Research Institute3 ; Wyeth Pharmaceuticalsl ,3sAbbott Laboratories, Inc . 1,3,5 ; Alkermes, Inc.3; AstraZeneca Pharmaceuticals LP 1,3; Cephalon, Inc .' ; DrugAbuse Sciences, Inca ; Forest Laboratories, Inc .' ; Lipha Pharma3; Ortho-McNeil Pharmaceutical, Inc .3; OyContral Pharma 3

DISCLOSURE INDEX

Presenter

Manufacturer(s)Jitender Sateen, M.D .

GlaxoSmithKline 5Norman H . Sartorius, M .D. Eli Lilly and Company'; Janssen-Cilag 1 ; Lilly' ; Lundbeckl; Wyeth Pharmaceuticals'Ayal Schaffer, M .D .

AstraZeneca Pharmaceuticals LP 1 '5; Biovail Corporations; Eli Lilly and Company' ,'; H. Lundbeck A/S5;Sanofi-Aventis3; Servier3

Alan F. Schatzberg, M.D .

Abbott Laboratories, Inc .' ; Aventis Pharmaceuticals, Inc .' ; Bristol-Myers Squibb Companyl'3; Eli Lilly andCompanyl'3 ; Forest Laboratories, Inc .' ; GlaxoSmithKline 1,3; Innapharma, Inc .' ; Janssen PharmaceuticaProducts, LP 1 ; Neuronetics, Inc .' ; Organon Pharmaceuticals Inc' ; Pfizer Inc . 1,6 ; Somaxon Pharmaceuticals' ;Somerset Pharmaceuticals Inc .1 . 3 ; Wyeth Pharmaceuticals' ,3

Thomas Schlaepfer

Cyberonics, Inc .'; Medtronics, Inc 3Lon S. Schneider, M.D .

Abbott Laboratories, Inc . 1,3,5 ; AstraZeneca Pharmaceuticals LP',3,5; Bristol-Myers Squibb Company5; Eli Lillyand Company' ,3s; Forest Laboratories, Inc . 1,3s ; GlaxoSmithKlinel ; Johnson and Johnson PharmaceuticalResearch and Developmentl ,3 ; Lundbeck5 ; Myriad Genetics, Inc . 1,3 ; Novartis Pharmaceuticals Corporation ),3 ;

Pfizer Inca ; Wyeth Pharmaceuticals)Nina R. Schooler, Ph.D .

AstraZeneca Pharmaceuticals LP 3 ; Bristol-Myers Squibb Companyl' 3; Eli Lilly and Company's ; ForestLaboratories, Inc.' ; Janssen Pharmaceutica Products, LP' ,3 ; Merck & Co., Inc .' ; National Institute of MentalHealth' ; National Institute on Drug Abuse' ; Organon Pharmaceuticals Inc' ; Pfizer Inc .1,3; Vanda Pharmaceuticals'

S. Charles Schutz, M.D .

Abbott Laboratories, Inc 3 ; AstraZeneca Pharmaceuticals LP',3,5; Eli Lilly and Company1,3,5

Gary J. Schummer, Ph.D . A.D.D. Treatment Centers 2Michael A . Schwartz, M .D. AstraZeneca Pharmaceuticals LP 3 .5; Bristol-Myers Squibb Company3. 5 ; Cephalon, Inc. 5 ; Eli Lilly and

Company 5 ; Janssen Pharmaceutica Products, LP 3 ; Johnson and Johnson Pharmaceutical Research andDevelopment3; Takeda Pharmaceuticals America, Inc . 5 ; Wyeth Pharmaceuticals 5

Thomas L. Schwartz, M .D . AstraZeneca Pharmaceuticals LP 5; Bristol-Myers Squibb Company3 .5; Cephalon, Inc . 3.5 ; Cyberonics, Incas ;

Forest Laboratories, Inca ; G1axoSmithKline5; Jazz Pharmaceuticals, Inc . 3 '5; Pfizer Inc.5; Sanofi-Aventis 5;Takeda Pharmaceuticals America, Inc . 5 ; Wyeth Pharmaceuticalsl ,5

Jan L. Scott, M.D .

AstraZeneca Pharmaceuticals LP 3 '5; Eli Lilly and Company3' 5 ; Janssen-Cilag5; Otsuka AmericaPharmaceutical, Inc .5 ; Sanofi-Aventis 5

David S. Shannahoff-Khalsa W.W. Norton & Co ., Inc 4Zafar Sharif, M .D .

Bristol-Myers Squibb Company, Janssen Pharmaceutica Products, LPs ; Bristol-Myers Squibb Company5 ;Janssen Pharmaceutica Products, LP5

M. Katherine Shear, M .D . Forest Laboratories, Inca ; Pfizer Inc .'

David V. Sheehan, M.D .

Abbott Laboratories, Inc . 1,3,5 ; Alexza MDC 1 ; AstraZeneca Pharmaceuticals LP'" 3 ; Avera Pharmaceuticals,Inc .' ; Bristol-Myers Squibb Company1,3,5 ; Cephalon, Inc . 1 .3; Cortex Pharmaceuticals, Inc' ; Cypress BioscienceInc .' ; Eisai Inca; Eli Lilly and Company1,3,5 ; Forest Laboratories, Inc . 1, 3; GlaxoSmithKline 1,3s ; JanssenPharmaceutica Products, LP',3,5 ; Jazz Pharmaceuticals, Inc 1 .3 ; Layton Biosciences, Inc1' 6 ; Mead Johnson3,s ;

Medical Outcome Systems, Inc . ; Merck & Co., Inc .' ,3= 5 ; Novartis Pharmaceuticals Corporation3 ; NovoNordisk Pharmaceuticals, Inc .5 ; Organon Pharmaceuticals Inc 1 '5; Ortho-McNeil Pharmaceutical, Inc . 5 ; Parke-Davis3' 5 ; Pfizer Inc . 1,3,5 ; Pharmacia & Upjohn' • 5 ; Roche Pharmaceuticals1 . 5 ; Sanofi-Aventis' ; Schering-PloughCorporations ; Shire Pharmaceuticals Group plc. 1 ; Solvay Pharmaceuticals, Inc ."5; TAP Pharmaceuticals,Inc 1,3,5 ; Warner Chilcott PLC3' 5 ; Wyeth Pharmaceuticals 1,3,5 ; ZARS Pharmal

Richard C . Shelton

Abbott Laboratories, Inc 3' 5 ; AstraZeneca Pharmaceuticals LP 3; Bristol-Myers Squibb Company5 ; Eli Lilly andCompany3.5; GlaxoSmithKline 3 .5; Janssen Pharmaceutica Products, LP1,3,5; Pfizer Inc. 1,3,5 ; Sanofi-Aventis3;Solvay Pharmaceuticals, Inc . 5 ; Wyeth Pharmaceuticals 3,5

Larry J . Siever, M.Ed.

Eli Lilly and Company' , 'Daphne Simeon, M.D .

National Institute of Health3

Gregory E . Simon, M.D .

Bristol-Myers Squibb Company' ; Wyeth Pharmaceuticals'Naomi M. Simon, M.D.

AstraZeneca Pharmaceuticals LP3; Cephalon, Inca ; Eli Lilly and Company3; Forest Laboratories, Inc 3'5;G1axoSmithKline 3; Janssen Pharmaceutica Products, LP 3; National Alliance for Research in Schizophreniaand Depression3; National Institute of Mental Health 3; Pfizer Inc. 3' 5 ; Sepracor, Inca; UCB Pharma3

Kelly H . Skelton, M.D .

AstraZeneca Pharmaceuticals LP5; Pfizer Inc. 5Andrew E. Skodol, M.D .

National Institute of Mental Health 3Gary W. Small

Abbott Laboratories, Inc . 1,5 ; Brainstorming Co . 1 ; Dakirnl' 6 ; Eisai Inc .' ,' ; Forest Laboratories, Inc . 1,5;

GlaxoSmithKline 3; Memory Fitness Institute ) >5 ; Myriad Genetics, Inc . 1 .5; Novartis PharmaceuticalsCorporationh5 ; Ortho-McNeil Pharmaceutical, Inc . 1.5 ; Pfizer Inc . 1,5 ; Siemensl ,a

Thomas E. Smith, M .D .

AstraZeneca Pharmaceuticals LP 5 ; Bristol-Myers Squibb Company' ; Eli Lilly and Company' ; JanssenPharmaceutica Products, LP 1 '5 ; Pfizer Inc .5

XXXIII

Presenter

Manufacturer(s)

Jordan W. Smoller, M.D .

Roche Pharmaceuticals'Mark Snowden, M.D .

Pfizer Inc. 5Claudio N . Soares, M .D .

AstraZeneca Pharmaceuticals LP 1 ; Berlex Inc . 5 ; Eli Lilly and Company3; GlaxoSmithKline 1,5; H. LundbeckA/S 1.5; National Alliance for Research in Schizophrenia and Depression3; Sepracor, Inc.'; WyethPharmaceuticals5

Mary Solanto, Ph.D .

McNeil Consumer Healthcarel ; Shire Pharmaceuticals Group plc . 1

Wesley E. Sowers

Deerfield Behavioral Health, Inc .'

Thomas J. Spencer, M .D .

Eli Lilly and Companyl,3 >5; GlaxoSmithKline' ,3,5 ; McNeil Consumer Healthcare',3,5 ; National Foundation forMental Health3 ; National Institute of Mental Health 3 ; Novartis Pharmaceuticals Corporation' ,3,5; Pfizer Inc. 1,3 ;

Shire Pharmaceuticals Group plc . 1,3,5 ; Wyeth Pharmaceuticals 5

Joyce Sprafkin, Ph .D .

Checkmate PlushStephen M. Stahl, M.Div.

Acadia Pharmaceuticals Inc' ; Asahi'; AstraZeneca Pharmaceuticals LP 1,3 ; Avera Pharmaceuticals, Inc . 1 ;Biovail Corporation'>3; Bristol-Myers Squibb Companyl'3; Cephalon, Inc .'"3 ; Cyberonics, Inc.' • 3 ; CypressBioscience Inc.1 " 3 ; Eli Lilly and Company'"3; EPIX'; Fabre Kramer Pharmaceuticals Inc .' ; Forest Laboratories,Inc.' •3; GlaxoSmithKline 1,3; H. Lundbeck A/S' ; Innapharma, Inc.' ; Janssen Pharmaceutica Products, LP',3 ;

Neurocrine Biosciences Inc? ,3; Neuromolecular Inc .' ; Neuronetics, Inc .' ; NovaDel Pharma Inc .' ; NovartisPharmaceuticals Corporation' ; Organon Pharmaceuticals Incl,3 ; Otsuka America Pharmaceutical, Inc .' ; PfizerInc . 1,3,5 ; Sanofi/Synthelabo' ; Sanofi-Aventis' ; Schering-Plough Corporation'; Sepracor, Inc . 1 .3 ; ShirePharmaceuticals Group plc.'" 3 ; Solvay Pharmaceuticals, Inc .' ; Somaxon Pharmaceuticalsl ,3 ; TetragenexPharmaceuticals Inc .' ; Wyeth Pharmaceuticalsl •3; Wyeth-Ayerst Laboratories3

Jodi E. Star, M.D .

AstraZeneca Pharmaceuticals LP 5

Murray B. Stein, M .D.

AstraZeneca Pharmaceuticals LP' ; Avera Pharmaceuticals, Inc . 1 ; Cephalon, Inc .' ; Eli Lilly and Companyl ,3 ; F.Hoffmann-La Roche & Co.1 . 3 ; Forest Laboratories, Inc .' ; GlaxoSmithKline 3 ; Jazz Pharmaceuticals, Inc .' ;National Institute of Mental Health 3; Solvay Pharmaceuticals, Inc .'; UCB Pharma'

Altha J . Stewart, M.D .

Pfizer Inc .'Paul Stiles, Ph .D .

Eli Lilly and Company3

Keith R. Stowell, M.D .

GlaxoSmithKline 4; Somaxon Pharmaceuticals¢Zachary N. Stowe, M.D .

Bristol-Myers Squibb Companyl • 5; Eli Lilly and Company5; GlaxoSmithKline1,3,5 ; Pfizer Inc. 3,5 ; WyethPharmaceuticals 1,3,5

Eric C. Strain, M.D.

Alkermes, Inc .' ; GlaxoSmithKlinel ; National Institute on Drug Abuse 3; Reckitt-Benkisers; Schering-PloughCorporations; Shire Pharmaceuticals Group plc .' ; Substance Abuse and Mental Health ServicesAdministration/ Center for Substance Abuse Treatment' ; Titan Pharmaceutical, Inc'

Katharine A . Stratigos, M.D. Shire Pharmaceuticals Group plc 4

Thomas S. Stroup, M.D .

Eli Lilly and Company' ; Janssen Pharmaceutica Products, LP 1 ; Pfizer Inc .'

Donna M. Sudak, M.D.

LWW - Author4Patricia Suppes, M.D .

Abbott Laboratories, Inc . 1.3; AstraZeneca Pharmaceuticals LP1,3,5 ; Bristol-Myers Squibb Company' ; Eli T .illyand Company'; GlaxoSmithKline',3,5 ; Janssen Pharmaceutica Products, LP 1 .3 ; JDS Pharmaceuticalsl ,3 ;

National Institute of Mental Health3; Novartis Pharmaceuticals Corporationh 3; Ortho-McNeilPharmaceutical, Inc.' ; Pfizer Inc .1,3 ; Shire Pharmaceuticals Group plc .' ; Solvay Pharmaceuticals, Inc .' ; StanleyMedical Research Institute3 ; UCB Pharma'; Wyeth Pharmaceuticals 3

Alan C. Swann, M.D .

Abbott Laboratories, Inc . 1,3,5 ; AstraZeneca Pharmaceuticals LP' ; CIBA 3; Eli Lilly and Company3s ;GlaxoSmithKline 1,3,5 ; Janssen Pharmaceutica Products, LP 1,3; Novartis Pharmaceuticals Corporation',3;

Ortho-McNeil Pharmaceutical, Inc .h 5 ; Parke-Davis 5 ; Pfizer Inc3,5 ; Shire Pharmaceuticals Group plc. 1,3 ; UCBPharma 3

Holly A. Swartz, M.D .

AstraZeneca Pharmaceuticals LP4; Bristol-Myers Squibb Company4,5; Eli Lilly and Company ; NationalInstitute of Mental Health3 ; Novartis Pharmaceuticals Corporation'; Pfizer Inc. 5

Marvin S. Swartz, M .D .

Eli Lilly and Companyh 3 ; GlaxoSmithKline' ; Pfizer Inc . 1,5

Robert M . Swift, M.D .

Alkermes, Inc .' ; Cephalon, Inc.'; Drug Abuse Sciences, Inca; Forest Laboratories, Inc . 1,3,5 ; National Instituteof Alcohol Abuse and Alcoholism3 ; Ortho-McNeil Pharmaceutical, Inc . 1,3; Oy Contral Pharma3; Pfizer Inc . 1,3

Carol A. Tamminga, M .D . Acadia Pharmaceuticals Inc'> 3; Johnson and Johnson Pharmaceutical Research and Development' ; NationalInstitute of Mental Health 1,3; Neurogen Corporation' ; Stanley Medical Research Institute'

Rajiv Tandon, M .D .

AstraZeneca Pharmaceuticals LP4; Bristol-Myers Squibb Company4; Eli T .illy and Company4;JanssenPharmaceutica Products, LP 4; National Institute of Mental Health 4; Otsuka America Pharmaceutical, Inc4 ;Pfizer Inc .4

Pierre N . Tariot, M.D .

Abbott Laboratories, Inc . 1 .3; AstraZeneca Pharmaceuticals LP1,3,5; Bristol-Myers Squibb Companyh 3 ; EisaiInc."; Elan Pharmaceuticals, Inca; Eli Lilly and Companyh 3 ; Forest Laboratories, Inc . 1,3,5;

DISCLOSURE INDEX

DISCLOSURE INDEX

Presenter

Janet Taylor, M .D .Humberto Temporini, M.D .Michael E . Thase, M.D .

Jean M. Thomas, M.D.Martin G . Tracy, J .D .Anton C. Trinidad, M.D .Madhukar H. Trivedi, M .D.

Paula T. Trzepacz, M.D .Guochuan E. Tsai, M.D .Phebe M. Tucker, M.D .

Douglas Turkington, M.D .Himanshu P. UpadhyayaJim Van Os, M.D .

Donna Vanderpool, J .D .Sanjay M . Vaswani, M.D .

Dawn I. Velligan, Ph.D.

Marcia L. Verduin, M.D .

Eduard Vieta, M.D .

Suzanne E .Vogel-Scibilia, M.D .

Mark S . Wallace, M.D .

B. Timothy Walsh, M.D .Peter J. Weiden, M .D .

Elyse D. Weiner, M.D .Daniel WeintraubSidney WeissmanMargaret D. Weiss, M .D .

Roger D. Weiss, Ph.D .

Manufacturer(s)

GlaxoSmithKline 1 '3 ; Janssen Pharmaceutica Products, LP' ; Merck & Co ., Inc . 1,3 ; Merck, Sharp, and Dohme1 ;Mitsubishi Pharmaceutical Corporationl ,3; Myriad Genetics, Inc . 1 .3; National Institute of Mental Health 3;National Institute on Aging3 ; Neurochem, Inc.1 . 3 ; Ono Pharmaceuticals, Inc.1,3 ; Pfizer Inc . 1,3.5 ; Sanofi-Aventisl ,3 ; Schwabe'; Takeda Pharmaceuticals America, Inc .' ; Wyeth Pharmaceuticalsl ,3

AstraZeneca Pharmaceuticals LP 5Abbott Laboratories, Inc .3 ; AstraZeneca Pharmaceuticals LP 5; Pfizer Inc.5AstraZeneca Pharmaceuticals LP 1 . 5 ; Bristol-Myers Squibb Company1 '5 ; Cephalon, Inc . 1 ; Cyberonics, Inc . 1,5;Eli Lilly and Company5; Forest Laboratories, Inc .' ; G1axoSmithKlineh 5; Janssen Pharmaceutica Products,LP1 ; Neuronetics, Inc .' ; Novartis Pharmaceuticals Corporation' ; Organon Pharmaceuticals Inc 1 =5; Pfizer Inc. 1 ;Sanofi-Aventis 5 ; Sepracor, Inc. 1 ; Shire Pharmaceuticals Group plc . 1 ; Wyeth Pharmaceuticals 1,5

National Institute of Mental Health 3Professional Risk Management Services, Inc 2McNeil Consumer Healthcare 3 ; Pfizer Inc . 5 ; Sanofi-Aventis 3; Wyeth Pharmaceuticals 3Abbott Laboratories, Inc .3 ; Bayer Corporation3; Bristol-Myers Squibb Companyl ,3,5; Cephalon, Inc. 3;Cyberonics, Inc . 1 "5; Eli Lilly and Companyl ,3 .5; Forest Laboratories, Inc . 1,3s ; GlaxoSmithKline3; JanssenPharmaceutica Products, LP1,3,5 ; Johnson and Johnson Pharmaceutical Research and Developmentl •3 ,5; MeadJohnson3; National Alliance for Research in Schizophrenia and Depression 3 ; National Institute of MentalHealth3 ; Organon Pharmaceuticals Inc 1 .3,5 ; Parke-Davis 3; Pfizer Inc . 1,3,5 ; Pharmacia & Upjohn1,3,5; PredixPharmaceuticals3; Sepracor, Inc . 1,5; Solvay Pharmaceuticals, Inc . 1,3,5 ; Wyeth Pharmaceuticals 1,3,5

Eli Lilly and Company' ,'Prestwick Pharmaceuticals, Inc 4AstraZeneca Pharmaceuticals LP3; Bristol-Myers Squibb Company3; Cephalon, Inc . 3; Forest Laboratories,Inc . 1,5; GlaxoSmithKline3 ; Ortho-McNeil Pharmaceutical, Inc . 3 ; Pfizer Inc . 3,5 ; Wyeth Pharmaceuticals" 3

AstraZeneca Pharmaceuticals LP5; Bristol-Myers Squibb Company5; Janssen-Cilag3,5

Abbott Laboratories, Inc .5 ; Cephalon, Inc 3; Eli Lilly and Company3; Shire Pharmaceuticals Group plc.'AstraZeneca Pharmaceuticals LP3; Bristol-Myers Squibb Company3; Eli Lilly and Company3;G1axoSmithKline3Professional Risk Management Services, Inc .2Abbott Laboratories, Inc .' ; Eli Lilly and Company5 ; Forest Laboratories, Inc .' ; GlaxoSmithKline5; PfizerInc . 5 ; Wyeth Pharmaceuticals5AstraZeneca Pharmaceuticals LP1,3,4,5 ; Bristol-Myers Squibb Company''¢; Eli T .illy and Companyl ,3 ;

InforMedix, Inc .' ; Janssen Pharmaceutica Products, LP1,3,4,5 ; Pfizer Inc . 1 s ,4sBristol-Myers Squibb Company3 ; Eli Lilly and Company 3; GlaxoSmithKline3; Janssen PharmaceuticaProducts, LP3; National Institute on Drug Abuse3; Office of Research on Women's Health3

AstraZeneca Pharmaceuticals LP1,3,5; Bristol-Myers Squibb Company1,3,5; Eli Lilly and Company1,3,5 ;GlaxoSmithKline 1,3 .5 ; H. Lundbeck A/S' ; Janssen Pharmaceutica Products, LP1,3,5; Janssen-Cilag1,3,5 ; Johnsonand Johnson Pharmaceutical Research and Developmenth 3; Lundbeckl; Merck, Sharp, and Dohmel ; NIHInstitute' ; Novartis Pharmaceuticals Corporationl ,3,5 ; Organon Pharmaceuticals Inc' ; Otsuka AmericaPharmaceutical, Inc . 1,3,5 ; Pfizer Inc . 1,3 .5 ; Sanofi-Aventisl ,3,5 ; Servier 1,3,5 ; Stanley Medical Research Institute 3 ;UCB PharmalAbbott Laboratories, Inc .5 ; AstraZeneca Pharmaceuticals LP 5; Bristol-Myers Squibb Company5 ; ForestLaboratories, Inc . 5; Pfizer Inc .5Abbott Laboratories, Inc .' ; Johnson and Johnson Pharmaceutical Research and Development' ; Pfizer Inc .5 ;Roche Pharmaceuticals)Abbott Laboratories, Inca ; Eli Lilly and Company3; GlaxoSmithKline 3; Ortho-McNeil Pharmaceutical, IncaAstraZeneca Pharmaceuticals LP1,3,5; Bristol-Myers Squibb Company1,3,5; Janssen Pharmaceutica Products,LP1,3.5 ; Johnson and Johnson Pharmaceutical Research and Developments ; Organon Pharmaceuticals Inc' ;Pfizer Inc . 1,3,5 ; Shire Pharmaceuticals Group plc . 5; Vanda Pharmaceuticals'Pfizer Inc . 5; Wyeth Pharmaceuticals 5Avanir Pharmaceuticals'Eli Lilly; Merck; OrganonCephalon, Inc .1,3,5; Eli Lilly and Company1,3s; Janssen Pharmaceutica Products, LP 1,3,5 ; NovartisPharmaceuticals Corporation1,3,5; Purdue Pharma L .P . 1,3,5 ; Shire Pharmaceuticals Group plc . 1,3,5

Abbott Laboratories, Inc .5 ; Alkermes, Inc .' ; Ortho-McNeil Pharmaceutical, Inca

PresenterJoyce C. West, Ph.D .

Timothy E. Wilens, M.D .

Jeffery N . Wilkins, M.D .Janet B.W. Williams, D .S.W.Solomon S. Williams, M.D .

M.E. Jan Wise, M .B.Ch.B .Thomas N . Wise, M.D .Jesse H. Wright III, M .D .Aysegul Yildiz-Yesiloglu, M.D.Monique Yohanan, M.D .M. Scott Young, Ph .D .Mary C. Zanarini, Ed.D .Phyllis C. Zee, M.D .

Mark Zimmerman, M .D .Sidney Zisook, M.D.

Joseph Zohar, M.D .Edward Zuzarte, M .D .

DISCLOSURE INDEX

Manufacturer(s)

AstraZeneca Pharmaceuticals LP3; Bristol-Myers Squibb Company3 ; Eli Lilly and Company3; JanssenPharmaceutica Products, LP 3 ; National Institute of Mental Health 3 ; Substance Abuse and Mental HealthServices Administration/ Center for Substance Abuse Treatment 3; Wyeth Pharmaceuticals 3

Abbott Laboratories, Inc .' ; Eli Lilly and Company3 '5; GlaxoSmithKline 1 ; Janssen Pharmaceutica Products,LPI ; National Institute of Mental Health' ; National Institute on Drug Abuse3; NeuroSearch A/S3 ; NovartisPharmaceuticals Corporations ; Ortho-McNeil Pharmaceutical, Inc . 3 '5; Pfizer Inc. 1 ; Saegis' ; Sanofi-Aventisl ;Shire Pharmaceuticals Group plc .3 s

Alkermes, Inc. 1,3 ; CME LLC1 ; Forest Laboratories, Inc . 3 ; Hythiam Inc . 1,3

American Psychiatric Press 4; Columbia University2 ; MedAvante, Inc . 1Boehringer-Ingelheim Pharmaceuticals 2Bristol-Myers Squibb Company5; Eli Lilly and Company5Eli Lilly and Company'Mindstreet4; Pfizer, GlaxoSmithKline5AstraZeneca Pharmaceuticals LP 3 ; GlaxoSmithKline3; Janssen-Cilag3 ; Pfizer Inc 3Elan Pharmaceuticals, Inc 4 ; Johnson and Johnson Pharmaceutical Research and Development6

Eli Lilly and Company3Eli Lilly and Company',3Kyowa Pharmaceuticals 3 ; Neurocrine Biosciences Inc . 1 ; Pfizer Inc .' ; Sanofi-Aventis 1 .5 ; TakedaPharmaceuticals America, Inc .',5

Bristol-Myers Squibb Company5; GlaxoSmithKline5; Wyeth Pharmaceuticals 5

Aspect Medical Systems3 ; Forest Laboratories, Inc . 5; GlaxoSmithKlineh5 ; National Alliance for Research inSchizophrenia and Depression 3 ; National Institute of Health3; National Institute of Mental Health 3; PamLab3

Lundbeck3; Pfizer IncaPfizer Inc . 5